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CHRISTY CASSARLY. Multistate Markov Models for Ordinal Functional Outcomes of 
Acute Onset Disease: Application in Acute Stroke Therapy Trials. (Under the direction of 
RENEE’ HEBERT MARTIN and YUKO Y. PALESCH)   
 The modified Rankin Scale (mRS), a seven-point ordinal scale ranging from no 
symptoms to death, is the most commonly used outcome measures in acute stroke therapy 
trials. Often, one visit is chosen for the primary analysis, and the scale is dichotomized 
leading to loss of information. Recently, alternative methods for analyzing the mRS have 
been explored. In addition, acute onset conditions require immediate attention and 
treatment, posing a challenge to assess baseline outcome measures for clinical trials. 
Thus, the mRS is not obtainable at baseline. Much of the progression or recovery 
experienced by a patient suffering from an acute onset disease is expected to occur early 
on. Moreover, typically, the goal of a treatment or therapeutic action is improvement in 
patient health compared to their baseline measure. To accurately quantify improvement, a 
measure of the outcome at baseline is ideal. This dissertation first explores the feasibility 
of multistate Markov models for the analysis of the mRS which allow for the full ordinal 
scale as well as the repeated measures data to be incorporated. The operating 
characteristics (type I error and power) of the multistate Markov model are compared 
with those from repeated logistic regression. Next, a framework is developed to predict 
and incorporate the latent baseline mRS score in a piecewise-constant multistate model. 
The last part of this work applies the piecewise-constant latent baseline model to real 
ix 
acute stroke trial data and compares the results with alternative methods for analysis of 
the mRS. 
1 
1 Introduction and Significance 
1.1 Overview and Specific Aims 
Ordinal response outcomes are often used in clinical trials. However, rather than 
analyzing the full ordinal scale, many trials choose to dichotomize the primary outcome. 
Although models used for dichotomous outcomes are easier to implement and tend to 
produce summary statistics with more clinically meaningful interpretations, 
dichotomization can result in a loss of statistical power [1]. Additionally, in trials where 
long-term follow-up is planned, the outcome is collected at multiple visits. Despite the 
availability of the repeated measures, many trials focus the primary analysis on the data 
from one visit, ignoring the additional outcome data. 
 One example of a therapeutic area that collects an ordinal outcome at multiple 
visits in clinical trials is acute stroke therapy. For many such trials, the modified Rankin 
Scale (mRS) score at 90 days post-randomization is used as the primary outcome 
measure [2]. The mRS is a seven-point ordinal scale that ranges from 0 (no symptoms) to 
6 (dead) and measures functional independence of stroke patients. It is commonly 
dichotomized to test the primary hypotheses of interest. 
 An emphasis has been placed on exploring alternative analytic methods for the 
analysis of mRS outcome data from acute stroke trials in recent years. Results indicate 
that the original structure of the scale needs to be maintained in analysis as much as 
possible [1, 3]. A number of alternative methods that preserve the ordinality of the mRS 
have been proposed. However, these methods have not been widely accepted in practice.  
2 
 The ultimate goal of a treatment or therapeutic action is to improve patient health 
compared to their baseline measure at presentation, immediately following an event. To 
accurately quantify improvement, a measure of the outcome at baseline would be ideal. 
Conditions with sudden onset, such as stroke, require immediate attention and treatment, 
posing a challenge to assess baseline outcome measures for clinical trials. Thus, the mRS 
is not obtainable at baseline making the quantification of “improvement” very 
challenging. 
 The multistate Markov model (MSMM) in continuous-time analyzes ordinal data 
and has been used to model the course of many diseases [4]. These models are 
advantageous in clinical applications where a disease process naturally moves through 
increasing stages of severity [4]. The feasibility of MSMMs for analysis of the mRS has 
not been previously considered. The mRS has more disease states (here, the seven levels 
of the scale) than most clinical applications of MSMMs. Most of the subjects that 
transition to a different state experience adjacent-state transitions, with only a few non-
adjacent state transitions. The combination of these two issues leads to a data structure, 
henceforth referred to as sparsely populated ordinal data, where small cell counts are 
observed for transitions to non-adjacent states. Currently, there is little information 
available regarding the appropriateness of MSMMs for sparsely populated ordinal 
outcomes.  
 This dissertation aims to address the issues presented here, and the specific aims 
of this research are as follows: 
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1. To explore the operating characteristics (type I error and power) of MSMMs 
compared with repeated logistic regression used to analyze sparsely populated 
repeated measures ordinal data.  
2. To develop a MSMM approach with piecewise-constant transition intensities that 
incorporates a latent baseline state. 
3. Analyze acute stroke therapy trial data using the methods developed in Aim 2 and 
compare the results with those from alternative methods previously suggested for 
the analysis of the mRS. 
 Realization of these aims will achieve the following: (1) feasibility of MSMMs 
for sparsely populated ordinal data will be demonstrated through investigation of sample 
size needed to achieve adequate power; (2) validity will be demonstrated through 
simulation studies where type I error is preserved; (3) efficiency of inclusion of the 
baseline mRS in the MSMM will be demonstrated; and (4) efficiency of the MSMM as 
compared with other methods for ordinal outcome data will be shown. 
1.2 Motivation and Clinical Relevance 
Each year, approximately 795,000 people have a stroke, 87% of which are ischemic [5]. 
Most randomized trials in acute stroke neuroprotection treatment have failed to show 
efficacy [3]. Several explanations have been proposed to describe the lack of positive 
trials in stroke, including heterogeneity in stroke pathophysiology, poor methodological 
and statistical standards, and incomplete preclinical testing [6]. One is poor study design 
and statistical methods, specifically, the analysis of the primary outcome [1]. The models 
that exist to fit dichotomous and continuous outcomes are easier to implement and tend to 
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produce summary statistics with more clinically meaningful interpretations. However, 
analysis of ordinal response outcomes are less straightforward. Thus, traditionally, many 
trials have dichotomized the ordinal mRS (Table 1.1) into success, scores of 0 or 1 (or 0 
to 2), or failure, scores greater than 1 (or 2), for the primary analysis, often collected at 90 
days post-randomization [7]. 
Table 1.1. Modified Rankin Scale. 
Score Description 
0 No symptoms at all 
1 
No significant disability despite symptoms; able to carry out all usual duties and 
activities 
2 
Slight disability; unable to carry out all previous activities but able to look after 
own affairs without assistance 
3 Moderate disability requiring some help, but able to walk without assistance 
4 
Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 
5 




 Some patients with severe stroke may never have the potential to achieve a 
“success” as defined by the dichotomy because they are so severely disabled at baseline. 
Patients with minor strokes may achieve a successful score more easily than those who 
are more disabled at baseline [8]. Thus, the prognostic heterogeneity of subjects does not 
allow for potential equal contribution to the treatment effect estimation for all subjects 
[9]. In general, ignoring these differences and dichotomizing the ordinal scale reduces 
statistical power [1]. Any reduction in power may result in failure to find a clinically 
meaningful treatment effect. In addition, the recovery and outcomes of subjects following 
a stroke realistically lie on a continuum. Categorical analysis of the ordinal scale provides 
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a more comprehensive quantification of the process than the analysis of the dichotomized 
scale [10]. 
 An additional drawback of the traditional analysis - dichotomization of the 90 day 
ordinal outcome - is the lack of use of available longitudinal data. Many acute ischemic 
trials assess and collect the mRS score at discharge and/or at 30 days from randomization 
and also at periodic intervals through 12 months, if long-term follow-up is planned in the 
trial. However, the longitudinal data are rarely used in the primary analysis. A more 
comprehensive clinical understanding of the treatment effect on outcome after a stroke 
may be better described using repeated measures analysis if improvement or worsening is 
expected beyond the 90 day primary outcome [11]. 
 Recently, an emphasis has been placed on exploring alternative outcomes as well 
as other analytic methods for the analysis of mRS data from acute stroke trials 
(continuous analysis- t-test, linear regression; ordinal analysis- shift analysis, 
proportional odds model, partial proportional odds model, adjacent categories logit 
model; sliding dichotomy; utility weighted mRS; repeated measures analysis). The 
literature indicates that the mRS should be analyzed in such a way that maintains the 
original structure of the scale as much as possible [1, 3]. Alternative analytic strategies 
proposed for analysis of the mRS have not been widely accepted in practice. These 
strategies are reviewed in depth in the following section. 
MSMMs are proposed to analyze the longitudinal mRS scores. An example of the 
typical structure of the observed transition matrices for the mRS over time is provided in 
Table 1.2. In this example, mRS outcome data from a mock acute stroke trial of 1,000 
subjects are observed for four follow-up visits to illustrate the structure of sparsely 
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populated ordinal data. The transitions that occur from one visit to the next are presented 
in each of the matrices.  
 
Table 1.2: mRS Transition Example. 
 
  
mRS at Time 2 
 
  











0 84 20 5 1 0 0 0 110 
1 45 79 17 2 1 0 1 145 
2 12 50 56 15 8 6 1 148 
3 2 25 46 63 17 3 0 156 
4 1 2 23 77 89 23 5 220 
5 0 0 2 7 41 48 22 120 
6 0 0 0 0 0 0 101 101 
 
Total 144 176 149 165 156 80 130 1000 
          
  
mRS at Time 3 
 
  











0 108 26 5 3 1 1 0 144 
1 38 123 12 2 0 1 0 176 
2 9 31 86 18 2 1 2 149 
3 3 5 32 116 8 1 0 165 
4 0 1 4 34 102 13 2 156 
5 0 0 0 2 18 45 15 80 
6 0 0 0 0 0 0 130 130 
 
Total 158 186 139 175 131 62 149 1000 
          
  
mRS at Time 4 
 
  











0 126 27 4 0 1 0 0 158 
1 21 146 14 4 1 0 0 186 
2 5 26 93 12 2 1 0 139 
3 0 4 28 129 11 1 2 175 
4 0 2 0 25 94 7 3 131 
5 0 0 0 1 10 34 17 62 
6 0 0 0 0 0 0 149 149 
 
Total 152 205 139 171 119 43 171 1000 
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In this example it is clear that the majority of subjects actually stay in the same 
state from one time period to the next as shown by the largest numbers along the main 
diagonal. The second largest numbers are to adjacent states and very few to non-adjacent 
states. For example, 79 of the 145 subjects that had mRS = 1 at Time 1 also had mRS = 1 
at Time 2. Only 17 of the 145 subjects with mRS = 1 at Time 1 transitioned to mRS = 2 
at Time 2. This is an example of an adjacent-state transition, one where a subject moves 
from one state (mRS = 1) to an adjacent state (mRS = 2). The other adjacent-state 
transition for mRS = 1 is the transition to mRS = 0. Throughout the table, a majority of 
observations are of subjects that remain in the same state, or have the same mRS score 
from one time to the next. Most of the subjects that transition to a different state 
experience adjacent-state transitions, with only a few non-adjacent state transitions.  
 In order to assess the application of the MSMM and number of states modeled, a 
literature review was conducted. Using the following keywords: multistate, Markov, 
panel, clinical, application, continuous-time, and excluding the following words: 
piecewise, non-homogeneous, inhomogeneous, semi-Markov, hidden Markov and 
random effects, a total of 40 articles were identified. An article was excluded if (a) the 
content was actually theoretical and there was no application, (b) it was a review with no 
new content, (c) multistate models were referenced, flagging it for review but the models 
were not actually fit, or (d) the models were actually discrete-time. Of the remaining 26 
articles, 25 fit models to data with five or fewer states and two fit models to data with six 
states [12-36]. One publication used a six-state model to analyze a dataset with much 
more data than is typically collected in acute stroke trials- approximately 5,000 patients 
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[37]. Thus, the feasibility of MSMM for analysis of sparsely populated ordinal data with 
a large number of states is unclear. 
 Currently, there is little information available regarding the appropriateness of 
MSMMs for sparsely populated ordinal outcomes with a large number of possible health 
states, as observed in longitudinal mRS data from acute stroke trials. In this dissertation, 
feasibility and operating characteristics of MSMMs applied to sparsely populated ordinal 
data are examined. In addition, a method is proposed to incorporate the latent baseline 
mRS score in longitudinal MSMMs. The mRS is unavailable at baseline and the 
aforementioned analytic techniques used for mRS data have adjusted for baseline severity 
using the National Institutes of Health Stroke Scale (NIHSS), a score that ranges from 0 
(no neurological deficit) to 42. Inclusion of the latent baseline mRS predicted using the 
baseline NIHSS and other baseline covariates in a MSMM could improve statistical 
efficiency to detect a significant treatment effect.  
1.2.1 Motivating Examples 
Data from two randomized double-blind, placebo-controlled acute stroke therapy trials 
are considered. The NINDS tissue plasminogen activator (t-PA) trial was designed to 
compare t-PA versus placebo in patients with acute ischemic stroke. The trial had two 
parts. Part 1 tested whether patients treated with t-PA had early improvement, as 
compared with those that were given placebo [38]. Part 2 was designed to determine 
whether there was a consistent and persuasive difference between the groups tested using 
four outcomes (Barthel Index, mRS, Glasgow Outcome Scale, and NIHSS) at 90 days 
modeled as a Global Test Score [39]. The Barthel Index is an index of independence that 
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scores the ability of patients to care for themselves [40]. Patients that can perform all 
assessed activities with complete independence are given a score of 100. The Glasgow 
outcome scale is a global assessment of function that ranges from 1 indicating good 
recovery to 5, death [41]. In order to be considered for inclusion for enrollment, there had 
to be deficiency measureable by the NIHSS. A total of 624 subjects were enrolled (291 in 
Part 1 and 333 in Part2), 312 in each group [38]. In Part 1, a benefit was observed for 
patients treated with t-PA in all four outcome measures. The primary analysis in Part 2, 
using generalized estimating equations, showed a significant global test score for the four 
outcomes [39]. Clinical and demographic characteristics can be found in the original 
paper [38]. 
 The Albumin in Acute Stroke (ALIAS) trial was a two part trial designed to 
compare 25% human serum albumin (ALB) and saline in patients with acute ischemic 
stroke. Part 1 consisted of two separate, concurrently implemented trials designed to 
assess whether ALB therapy improved neuroprotection beyond standard of care in two 
cohorts of patients [42]. One cohort consisted of subjects that received standard 
thrombolytic therapy (intravenous t-PA, intra-arterial t-PA, endovascular mechanical 
thrombolysis or a combination of intravenous and endovascular treatment) and the other 
was subjects who were not thrombolysed. Part 1 was suspended for safety reasons after 
434 subjects (207 albumin and 217 saline) were enrolled. More patients died in the first 
30 days in the ALB group than the placebo group and deaths were increased in patients 
older than 83 years and patients that received excessive intravenous fluids. The study 
design for Part 2 was modified based on the safety findings in Part 1. The primary 
endpoint was a composite outcome defined as a NIHSS 0-1 and/or mRS 0-1 at 90 days 
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from randomization. Only patients with a baseline NIHSS of 6 or above were eligible for 
enrollment in the trial. Part 2 was stopped early for futility after 841 subjects were 
randomized (422 to albumin and 419 to saline). Clinical and demographic characteristics 





2.1 Previous Analytic Methods for Ordinal Outcomes 
In this section, alternative analytic approaches to dichotomized analysis for the mRS are 
explored. A summary of all of the methods is provided in Table 2.1.  
2.1.1 Continuous Analysis 
In general, analysis of continuous variables with the t-test and linear regression is 
straightforward and produces clinically intuitive summary statistics. When these methods 
are applied to ordinal scales, the results are less interpretable. Non-integer values from an 
ordinal scale do not have a clear meaning when they are considered to be continuous. 
When compared to ordinal analysis, continuous analysis has been shown to have 
comparable power; however, the normality assumption is not met in most studies of 
stroke outcome [3]. In order to consider an ordinal outcome to be continuous, the sample 
size must be large enough for the normal approximation to be valid. Even in large 
datasets, the mRS is skewed and there are no recommendations on how to normalize it.  
2.1.2 Shift Analysis 
The Cochran-Mantel Haenszel (CMH) shift test, or the van Elteren test, can be used to 
analyze the distribution of ordinal data [7]. This test can show whether a treatment causes 
a significant favorable shift toward better outcome. Shift analysis can account for ordered 
categories, has no distributional assumptions and is easy to implement. However, it is not 
feasible for large scale clinical trials with non-simple randomization schemes as it only 
allows for a limited number of covariates. Logistic regression can be used in conjunction 
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with the shift analysis to provide an estimate of treatment effect because there is not an 
associated odds ratio (OR) or effect size produced from the CMH test [44].  
2.1.3 Ordinal Analyses 
The proportional odds model (POM) assumes an identical effect of the predictors for 
each cumulative probability [45]. In other words, the OR comparing treatment to placebo 
in patients with mRS of 0 versus 1-6 is assumed to be the same as the OR for mRS of 0-1 
versus 2-6, and so on. If the proportional odds assumption holds, statistical power can be 
increased compared to analysis using a strict dichotomy. If the assumption fails, this 
analysis could mask important effects at one end of the ordinal outcome [46]. The score 
test for assessing the proportional odds assumption is anticonservative and DeSantis and 
colleagues illustrated the lack of power of the score test using the data from the NINDS t-
PA trial [46]. The score test failed to reject the assumption of proportional odds (p = 
0.06); however, a plot of the cumulative log odds of each mRS score for each treatment 
group indicated that the assumption may be inappropriate.  
The partial proportional odds model (PPOM) can be used when the proportional 
odds assumption does not hold [46]. In general, there are two types of PPOMs, an 
unconstrained and a constrained model [47]. The unconstrained PPOM produces cut-off 
point-specific odds ratios. Alternatively, if a pattern is expected in the cut-off point-
specific odds ratio, for example a linear trend, constraints could be placed on the 
parameter to obtain an appropriate fit. A linear trend occurs when the violation of the 
proportional odds assumption is in one direction. This model includes an additional 
parameter that allows for the ORs to increase proportional to the outcome scale. One 
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drawback of this model is that it could require a larger sample size to be adequately 
powered. 
The adjacent categories logit model (ACAT) is another logistic regression model 
that does not require the proportional odds assumption. These models utilize single-
category probabilities rather than cumulative probabilities [45]. Rather than effects that 
refer to the entire response scale in the POM, the ACAT effects refer to the effect of a 
predictor on the response in any two adjacent categories. As with the PPOM, the ACAT 
model may require a larger sample size to be adequately powered to detect a treatment 
effect. 
2.1.4 Sliding Dichotomy Analysis 
The sliding dichotomy (or the more generalized sliding trichotomy or tetrachotomy) 
allows for the definition of success to vary based on patient-specific baseline prognostic 
variables while maintaining a dichotomized outcome [48]. Re-analysis of acute stroke 
therapy trials uses pre-specified cut-points for prognosis group definition based on the 
NIHSS score [49]. The sliding dichotomy can be used to define “mild”, “moderate”, and 
“severe” stroke using the baseline NIHSS score and defines “success” for each of the 
three groups. One example is to define favorable outcome as mRS = 0 for mild strokes, 
mRS = 0-1 for moderate strokes and mRS = 0-2 for severe strokes. Since baseline 
severity is such a strong predictor of outcome in stroke patients, this baseline severity 
adjusted approach has been considered for use over the traditional dichotomy [48]. 
 Some simulation studies have shown that the utilization of the sliding dichotomy 
provides higher sensitivity to detect true treatment effects [50]. For example, when the 
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probability of favorable outcome is high (greater than 0.5), the sliding dichotomy 
provides higher power [9]. This is not a general result; however, as other studies have 
determined that the traditional dichotomy is more powerful than the sliding dichotomy in 
most situations [51]. When the probabilities of favorable outcome are lower, the 
traditional dichotomy is more powerful [9]. 
 While the sliding dichotomy has the potential to be a powerful tool in some 
settings, it also has limitations. Determining the number of prognostic groups to use is not 
an obvious decision and can be difficult to justify. In addition, determining how to choose 
the cut points for the different groups can be a difficult task. Although using three groups 
(mild, moderate and severe) is used in the literature [48], methods used to determine 
severity cut points vary and need to be verified. Poor selection of the number of groups 
and cut points could result in a loss of power. In addition, while the sliding dichotomy 
allows for a baseline severity adjusted outcome, it still ignores any non- “success” 
transition from one mRS score to another even though each mRS category (except 5 to 6) 
represents a clinically meaningful difference in health state [52]. 
2.1.5 Utility-Weighted mRS 
A recently proposed approach to transform the mRS into a patient-centered outcome 
measure is the utility-weighted mRS (UW-mRS) [53]. The chosen patient-centered 
outcome measure, utility, is the desirability of a specific health outcome to a patient [54]. 
Utility weights for each level of the mRS were derived by averaging values derived in 
two prior studies. The first study mapped mRS scores to the European Quality of Life 
Scale (EQ-5D) in transient ischemic attack survivors from a population-based study in 
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Great Britain [55]. The second study derived weights using the methodology of the 
World Health Organization Global Burden of Disease Project [56]. Using the utility 
weights is straightforward, and the UW-mRS is analyzed using continuous analysis. 
Although this method is easy to implement and may provide greater statistical power, it is 
based on only two populations and may not be generalizable to other populations. In 
addition, the utility values are limited with respect to interpretation compared to other 
methods. 
2.1.6 Longitudinal Analysis  
Generalized estimating equations (GEE) can be used to estimate parameters for outcomes 
collected at multiple time points [57]. This approach allows for covariate adjustment 
while incorporating within-patient correlation. GEE analysis has been used to analyze the 
repeated measures of the mRS [11, 58]. Analysis of the longitudinal dichotomized 
outcomes yields clinically meaningful odds ratios. However, as the models increase in 







Table 2.1. Summary of statistics obtained from each type of analysis of the mRS. 





The odds of good outcome in 
the treatment group versus 
placebo 
 Easy to apply 
 Easy to interpret 
 Clinically intuitive 
 Can result in a loss of power 






Improvement of the average 
mRS score in patients that 
received treatment 
 Easy to apply 
 
 No straightforward interpretation 
 Normality assumption is often not met 






The treatment group shifted in a 
favorable direction toward a 
better mRS score versus 
placebo 
 Easy to apply 
 Accounts for ordered categories 
 No distributional assumptions 
 Accommodates a limited number of 
covariates 




The odds of a lower mRS the 
treatment group versus placebo 
 Easy to apply 
 Clinically meaningful summary 
odds ratio 
 May yield biased estimate if proportional 
odds assumption is not met 
 Anticonservative score test 
PPOM ORs for six 
dichotomies 
of mRS 
Treatment has a significant 
benefit for certain definitions of 
good outcome 
 Does not require proportional 
odds assumption 
 Less straightforward summary odds ratios 
 Can require a larger sample size to be 
adequately powered 
ACAT  ORs for six 
adjacent 
categories  
The treatment group is more 
likely to have smaller mRS for 
certain adjacent mRS scores  
 Does not require proportional 
odds assumption 







OR The odds of good outcome 
(defined by baseline severity) 
in the treatment group versus 
placebo 
 Easy to apply 
 Easy to interpret 
 Clinically intuitive 
 Less power in some scenarios 
 Choosing groups and cut-points poorly 







Improvement of the average 
utility score in patients that 
received treatment 
 Easy to apply 
 Can increase power 
 May not be generalizable to other studies 





OR The odds of good outcome over 
the 12-month period in the 
treatment group versus placebo 
 Utilizes all longitudinal data 
 Clinically meaningful odds ratio 
 
 More complicated modeling 






The hazard (instantaneous risk) 
of transitioning from one mRS 
state to another in the treatment 
group versus placebo  
 Utilizes full ordinal scale 
 Utilizes all longitudinal data 
 Estimates transition rates for 
progression and recovery  
 Difficulty in estimating sample size 





2.2  Multistate Markov Models 
2.2.1 General Multistate Markov Models 
MSMMs are an alternative approach to analyze repeated measures data with an ordinal 
outcome. These types of models describe how a process moves between states over time, 
which is desirable in the description of disease processes that naturally move through 
increasing stages of severity [59]. MSMMs can provide a better clinical understanding of 
the disease process since the information from the entire course of the disease is used to 
estimate the parameters of the model. These models have been used in numerous clinical 
applications including: multiple sclerosis [60], periodontal disease [61], alcoholism [62], 
and psychiatry [63]. 
 Figure 2.1 represents a general MSMM with four states. The arrows indicate that 
a transition can occur between any two states. The model estimates parameters describing 
each of the allowable transitions.  
 





 The use of MSMMs requires that the Markov property holds for the observed 
data. Consider a system with a finite state-space {1,2,3,..., }I , where I  represents 
the number of states. Let ( )X s t  be a discrete random variable that indicates the state 
occupied by the system at time s t . Let ( )F { ( ) : }X s X v v s  which denotes all 
information pertaining to the history of X  up to time s  [64]. A series of observations 
has the Markov property if the conditional distribution of ( )X s t given ( )FX s , satisfies 
    ( )( ) | F , ( ) ( ) | ( ) ( , ), ,X s ijP X s t j X s i P X s t j X s i p s t i j           (2.1) 
In other words, the present state depends only on the immediately preceding observation 
and not on the ones that precede it.  
 MSMMs may be defined for both discrete time and continuous. Although the 
course of disease is a continuous process, clinical trials often only collect data at 
intermittent follow-up visits. In the context of stroke, the exact time of progression or 
recovery, or change of state, of disease is not observed. Data of this type, representative 
of a continuous process yet observed at discrete time points, is referred to as panel data 
[65]. Both discrete and continuous time MSMMs can be used to describe panel data. In 
many acute stroke trials, the mRS is collected at follow-up visits that are not evenly 
spaced. In such instances, continuous time models are appropriate. A continuous model 
for panel data can only be used in cases where the sampling times are considered to be 
non-informative [66]. An example of non-informative sampling is a fixed observation 
scheme, where the interval of follow-up is specified in advance. However if observations 




technique is not appropriate without properly adjusting for the additional information 
[66]. For instance, these models cannot be used in a scenario where observations occur 
when a subject visits a doctor because they are in poor-condition. A model that 
incorporates the information from the sampling times must be used for this type of self-
selected follow-up outcome data. In acute stroke trials, the follow-up visits are usually 
specified in advance and are non-informative so continuous modeling is appropriate. 
 A common assumption of continuous-time MSMMs is that of homogeneity, 
where transition probabilities remain constant over time. When homogeneity is assumed, 
the transition probabilities, ( )ijp t , are defined as  
 ( ) { ( ) | ( ) } { ( ) | (0) }ijp t P X s t j X s i P X t j X i        . (2.2) 
Since this expression does not depend on s , the transition from state i  to state j on a 
time interval of length t  has the same probability at any time. The ( )ijp t  are elements of 
the transition probability matrix, ( )tP . 
In order to construct continuous time Markov chains, the amount of time the 
process will remain in a state, i  must be determined. Suppose (0)X i  and let iT  
represent the amount of time a process stays in i  after entering. To derive the distribution 
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Pr{ ( ) for [ , ] | ( ) } (Markov property)
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T  satisfies the memoryless property and follows the exponential distribution.  
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   . (2.3) 
The intensities represent the instantaneous rate of moving from state i  to state j i  and 





  .  
 In each of the continuous time Markov chain constructions only the local behavior 
of the process is known. To determine the global behavior of the process, Kolmogorov 
differential equations to solve for the terms  
 ( ) Pr{ ( ) | (0) }ijp t X t j X i   . 
These are a system of ordinary differential equations describing the probabilities ( )ijp t . 
Two sets of Kolmogorov equations exist, forward and backward differential equations. 




a future time. Backward differential equations are used to describe what happened at a 
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Using the fact that 
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   the generator matrix of the Markov chain, ijA , is 
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Finally, the system of equations can be solved 
 ( ) (0) tA tAP t P e e    
where 
tAe  is the matrix exponential and (0)P  is the identity matrix. The matrix 








  [59]. (2.5) 
For simple models ( )P t  can be calculated in terms of A  algebraically. In more complex 
cases, the Kolmogorov equations define a system of equations that cannot be solved 
analytically. If the eigenvalues of A  are distinct, eigen-decomposition can be used to 




 Let B  be a diagonal matrix consisting of the eigenvalues and C  be a matrix with 
corresponding eigenvectors as the columns. If distinct eigenvalues exist, C  can be 
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     [67]. (2.6) 
The model parameters are estimated using maximum likelihood estimation with 
numerical optimization. Once the parameters are estimated, the likelihood can be 
calculated. 
 Suppose X  is observed over 0 1 2 ... Mt t t t    . Let 0 1 2, , , ..., Mi i i i be the 
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where 0iP  is the initial probability that the process is at 0i . For a series of observations 
0,..., zznzx x  at times 0,..., zznzt t  for patients 1,...z N , with covariate vectors ip  and 
model parameters   , the log-likelihood is  
 
( 1) ( 1)
1 1




x x i i i
z
l p t t 
 
 
  [59]. (2.9) 
 Application of MSMMs requires the user to consider which transitions can 
realistically occur in continuous time. When the states represent levels of disease severity 
it is assumed that in order for a subject to travel from one state to a non-adjacent state, the 
subject also had to travel through the intermediate states [59]. For example, if a transition 
from state 3 to state 1 is observed, it is assumed that the subject traveled through state 2 
at some point as well. Thus, in these applications, a reduced transition intensity matrix 
where non-adjacent state intensities are fixed to equal zero should be assumed, with the 
exception of transitions to death. If a state represents death it is called an absorbing state 
since transitions from death cannot occur. Figure 2.2 displays a general continuous 
MSMM for panel data where the states represent disease severity and state k is death. The 






Figure 2.2:  General MSMM for disease severity. 
 
2.2.2 Piecewise-constant Multistate Markov Models 
In the case of ischemic stroke occurrence and treatment, patients can get better or worse 
very quickly during the acute phase immediately after occurrence. For this reason, the 
time homogeneity assumption is expected to fail for the first transition, from the 
predicted baseline to the first observed outcome which typically occurs at one week or 
one month post stroke onset. Therefore, the assumption of homogeneity is relaxed and a 
non-homogeneous model is considered. 
  The MSMM for panel data can be extended to accommodate piecewise-constant 
intensity matrices for the non-homogeneous case [59]. Here, the transition probability 
functions are dependent on s , and the transition matrix function is ( , ) ( ( , ))ijs t p s tP . 
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   .  (2.10) 
The time-homogeneity assumption can be tested by using a likelihood ratio test to 
compare the time-homogenous model to piecewise-constant models with different cutoff 
times. 
2.2.3 Predictors 
The effect of a predictor, specifically treatment, is incorporated into the model as 
transition intensity functions [69]. Let z be a vector of observed predictors then 
 ( ; ) ( )exp( ' ( )), ( ) 0ij ij ij ijt z t z t t       (2.11) 
where ( )ij t  is the parameter vector associated with the predictor vector z  in the 
transition between states i  and j  in time t . The transitional rates are represented by
( ; )ij t z  at time t  for the patients with vector z . 
2.2.4 Application of MSMMs to the mRS 
mRS data collected from acute stroke trials is used to demonstrate the aforementioned 
MSMM methodology. Although MSMMs have been used to describe a number of 
disease processes [60-63, 70], currently literature is lacking applications of these models 
on data with a larger, i.e. more than four, number of states. With disease represented as 
seven states the mRS is a good example of where the application can be expanded. Also 
the mRS is collected at discrete time points, the disease process itself is not discrete, thus 




the NINDS t-PA trial and the ALIAS trial. In the NINDS t-PA trial, the observations 
occurred at 7-10 days, 90 days, 180 days, and 360 days [38]. The mRS was collected at 
30 days, 90 days, 180 days, 270 days, and 360 days for ALIAS [43]. Because the 
observations are not evenly spaced a discrete model is not appropriate, and a continuous-
time MSMM is used. 
 The states of this model represent the seven levels of the ordinal mRS scale. The 
nature of the mRS and the follow-up schedule lead to a sparsely populated matrix of 
observed transitions. Tables 2.2 and 2.3 show the state tables of the frequency of 
transitions for NINDS t-PA and ALIAS, respectively. The rows represent the state to 
which a subject begins, and the columns represent the state into which the subject 
transitions. These tables include all transitions over the course of follow up. For example, 
for the NINDS t-PA trial, there were 196 observations where the mRS for a subject was 0 
for two consecutive time points (including from 7-10 days to 90 days, 90 days to 180 
days and 180 days to 360 days). 
As previously described, a large proportion of the observed pairs of the mRS are 
for subjects that do not transition and remain in the same state. The transitions that do 
occur are largely adjacent state transitions. Though non-adjacent state transitions are 
observed, it is assumed that a subject passed through the intermediate states; the 
transitions were not captured because the mRS was observed at discrete times. This data 
structure is unlike data in published applications of MSMMs. First, most other models 




the transitions are sparse. The feasibility of MSMMs for this type of data needs to be 
determined.  
Table 2.2. Frequency of mRS Transitions in NINDS t-PA.  
 
0 1 2 3 4 5 6 
0 196 46 4 0 1 0 1 
1 62 224 23 4 4 1 5 
2 6 53 73 20 4 0 7 
3 6 21 48 137 9 3 6 
4 3 18 23 78 156 21 28 
5 0 2 2 14 53 79 75 
 
Table 2.3. Frequency of mRS Transitions in ALIAS.  
 
0 1 2 3 4 5 6 
0 524 98 13 6 3 1 2 
1 158 542 85 19 4 0 2 
2 31 175 432 53 7 1 3 
3 7 48 150 417 43 4 5 
4 1 7 28 136 391 37 9 
5 0 1 0 7 60 100 23 
 
In order to determine the feasibility of MSMMs for analysis of sparsely populated 
ordinal data, the operating characteristics of MSMMs are compared with repeated logistic 
regression in Chapter 3 of this dissertation. Once the feasibility is assessed, a MSMM 
approach with piecewise-constant transition intensities incorporating a latent baseline 
state is developed in Chapter 4. Finally, in Chapter 5, the methods developed in Chapter 4 
are applied to acute stroke therapy trial data and are compared with results from the 
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Ordinal outcomes collected at multiple follow-up visits are common in clinical trials. 
Sometimes, one visit is chosen for the primary analysis and the scale is dichotomized 
amounting to loss of information. Multistate Markov models describe how a process 
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limited non-adjacent state transitions. The results suggest that the multistate Markov 
models preserve the type I error and adequate power is achieved with modest sample 











Most randomized trials in acute stroke neuroprotection treatment have failed to show 
efficacy for new interventions [3]. Mergenthaler and Meisel (2012) provide several 
explanations to describe the lack of positive trials in stroke including heterogeneity in 
stroke pathophysiology and incomplete preclinical testing [6]. Two of the explanations 
cited by the Optimising Analysis of Stroke Trials Collaboration are inadequate study 
designs and inappropriate statistical methods, specifically the analysis of the primary 
outcome [1]. 
 The modified Rankin Scale (mRS) score at 90 days post-randomization is a 
commonly used primary outcome measure in Phase III clinical trials of acute stroke 
therapy [2]. The mRS is a seven-point ordinal scale that measures degree of disability of 
stroke patients (Table 3.1).  
Table 3.1. Modified Rankin Scale. 
Score Description 
0 No symptoms at all 
1 
No significant disability despite symptoms; able to carry out all usual duties and 
activities 
2 
Slight disability; unable to carry out all previous activities but able to look after 
own affairs without assistance 
3 Moderate disability requiring some help, but able to walk without assistance 
4 
Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 
5 




 Analyzing the mRS as an ordinal scale has only recently gained acceptance [1, 3, 




to 2), or failure, scores greater than 1 (or 2), for the primary analysis [7]. Though models 
used for dichotomous outcomes are easier to implement and some prefer the clinically 
meaningful interpretations, dichotomization can result in a loss of statistical power [1]. It 
is intuitive that some patients with severe stroke may never have the potential to achieve 
a success as defined by the dichotomy. Thus, the prognostic heterogeneity of subjects 
does not allow for potential equal contribution to the estimation of the treatment effect for 
all subjects [9].  
 Recently, an emphasis has been placed on exploring alternate analytic methods 
for the mRS outcome data from acute stroke trials. Results indicate that the mRS should 
be analyzed in such a way that maintains the original structure of the scale as much as 
possible [1, 3]. Linear regression and analysis of variance have been suggested to analyze 
the mRS scale as a continuous variable. Although results from these models are generally 
intuitive, the application to the mRS leads to summary statistics that will not have a clear 
interpretation. Non-integer values from an ordinal scale do not have a clear meaning 
when they are treated as continuous.  
 Another popular alternative method for mRS outcome data is sliding dichotomy 
analysis. The sliding dichotomy method allows for the definition of success to vary based 
on patient-specific baseline prognostic variables while maintaining a dichotomized 
outcome [48]. Commonly, re-analysis of acute stroke trial data using the sliding 
dichotomy defines pre-specified cut-points for prognostic group inclusion based on the 
National Institutes of Health Stroke Scale (NIHSS) score [49]. The mRS is unavailable 




baseline severity using the NIHSS, a score that ranges from 0 (no neurological deficit) to 
42. Often, three prognostic groups are defined using the baseline NIHSS for the sliding 
dichotomy as ‘mild’, ‘moderate’, and ‘severe’ and the definition for ‘success’ differs for 
each group. One example is to define favorable outcome as mRS = 0 for mild strokes, 
mRS = 0-1 for moderate strokes and mRS = 0-2 for severe strokes. Since baseline 
severity is a strong predictor of outcome in stroke patients, this baseline severity adjusted 
approach has been considered for use over the traditional dichotomy.  
 While the sliding dichotomy has the potential to be a powerful tool in some 
settings, it has limitations. Some simulation studies have shown that the utilization of the 
sliding dichotomy provides higher sensitivity to detect true treatment effects [50]. For 
example, when the probability of favorable outcome is high (greater than 0.5), the sliding 
dichotomy provides higher power [9]. This is not a general result; however, as other 
studies have shown that the traditional dichotomy is more powerful than the sliding 
dichotomy in many situations [51]. When the probability of favorable outcome is lower, 
the traditional dichotomy is more powerful [9]. In addition, determining the number of 
prognostic groups to use is not an obvious decision and can be difficult to justify. 
Moreover, determining how to choose the cut points for the different groups can be a 
difficult task. Although the use of three groups (mild, moderate and severe) is common in 
the literature, methods used to determine severity cut points vary and need to be verified 
[48]. Poor selection of the number of prognostic groups and cut points could result in a 
loss of power. Furthermore, while the sliding dichotomy allows for a baseline severity 




another even though each mRS category (except 5 to 6) represents a clinically 
meaningful difference in health state [52]. The recovery and outcome of subjects 
following a stroke realistically lies on a continuum. Ordinal analysis of the mRS scores 
can provide a more complete understanding of this process than analysis of the 
dichotomized scale [10].  
 Recently, methods using the full ordinal scale have been demonstrated [3, 46, 71]. 
The proportional odds model is a cumulative logistic regression model that has been 
proposed for analysis of mRS outcome data, Use of this model requires the assumption of 
proportional odds- the odds ratio comparing treatment to control in subjects with mRS = 
0 versus 1-6 is the same as the odds ratio for mRS = 0-1 versus 2-6, and so on. In data 
where the proportional odds assumption does not hold, shift analysis, an assumption-free 
ordinal test, can be used [7]. Shift analysis can be performed using the van Elteren test, 
an extension of the two-sample Wilcoxon rank-sum test. Though shift analysis does not 
require assumptions, it does not produce a summary statistic which is often desired by 
clinicians. Alternatively, in cases where the proportional odds assumption is 
unreasonable, the partial proportional odds model or adjacent categories logit model can 
be used. The partial proportional odds model includes an additional term to allow for the 
odds ratios to increase proportional to the outcome scale [46]. The adjacent categories 
logit model calculates odds ratios for each adjacent category of response in relation to 
covariates. Both of these models are more flexible than the proportional odds model but 




 An additional drawback of focusing the primary outcome on the 90-day time 
point is the lack of use of available longitudinal data. Many acute stroke trials collect the 
mRS at discharge and/or at 30 days from randomization and also at periodic intervals 
through 12 months, if long-term follow-up is planned. The longitudinal data are not often 
used in the primary analysis. Repeated measures analysis, which incorporates outcome 
data from all follow-up visits, may provide a more comprehensive clinical understanding 
of the treatment effect on outcome after a stroke [11].  
Table 3.2. mRS transition example. 
 
  
mRS at time 2 
 
  











0 84 20 5 1 0 0 0 110 
1 45 79 17 2 1 0 1 145 
2 12 50 56 15 8 6 1 148 
3 2 25 46 63 17 3 0 156 
4 1 2 23 77 89 23 5 220 
5 0 0 2 7 41 48 22 120 
6 0 0 0 0 0 0 101 101 
 
Total 144 176 149 165 156 80 130 1000 
          
  
mRS at time 3 
 
  











0 108 26 5 3 1 1 0 144 
1 38 123 12 2 0 1 0 176 
2 9 31 86 18 2 1 2 149 
3 3 5 32 116 8 1 0 165 
4 0 1 4 34 102 13 2 156 
5 0 0 0 2 18 45 15 80 
6 0 0 0 0 0 0 130 130 
 
Total 158 186 139 175 131 62 149 1000 
 
 In this article, a novel approach using multistate Markov modeling is proposed for 




and provides clinically relevant summary statistics to describe treatment effect. The mRS 
has more disease ‘states’ (here, the seven levels of the ordinal response) than many 
previously considered clinical applications of multistate Markov models. An example of 
the typical data structure of the observed mRS could be illustrated in Table 3.2. In this 
example, mRS outcome data from a mock acute stroke trial of 1,000 subjects was created 
for three follow-up visits. The ‘transition’ from one state to another that occurred from 
one visit to the next is described in Table 3.2. For example, 79 of the 145 subjects that 
had mRS = 1 at time 1 also had mRS = 1 at time 2. Only 17 of the 145 subjects with mRS 
= 1 at time 1 transitioned to mRS = 2 at time 2. This is an example of an ‘adjacent-state’ 
transition. Throughout the table, a majority of the observations are instances where the 
subjects remained in the same state, or had the same mRS score from one time to the 
next. Most of the subjects that transitioned to a different state display adjacent-state 
transitions, with a limited number of non-adjacent state transitions.   
 A literature review conducted of an online database yielded a total of 40 articles 
using the following keywords: multistate, Markov, panel, clinical, application, 
continuous-time, and the following excluded words: piecewise, non homogeneous, 
nonhomogeneous, inhomogeneous, semi Markov, hidden, random effects. An article was 
excluded if (a) the content was actually theoretical and there was no application, (b) it 
was a review with no new content, (c) multistate models were referenced, flagging it for 
review but the models were not actually fit, or (d) the models were actually discrete-time. 
Of the remaining 26 articles, 25 fit models to data with five or fewer states and two fit 




a dataset with much more data than is typically collected in acute stroke trials- 
approximately 5,000 patients [37].  
 The multistate Markov model is introduced in Section 3.2. The main focus of the 
paper is to approximate the power and type I error probabilities for multistate Markov 
models of data structures similar to the longitudinal mRS outcomes observed in acute 
stroke trials. In Section 3.2, continuous-time multistate Markov models are defined and 
the simulation scenarios for estimation of the operating characteristics of these models 
are described. In Section 3.3, the type I error probabilities and power are approximated 
for varying design elements and power of the multistate models is compared with that of 
repeated measures logistic regression. In Section 3.4, the findings are summarized and 
discussed. 
3.2 Methods 
Multistate Markov modeling is an alternative approach to analyze repeated measures data 
with an ordinal outcome. The multistate Markov model describes how a process moves 
between states over time, which is desirable in the description of disease processes that 
naturally move through increasing stages of severity [4]. Subjects can improve and 
worsen over the course of follow-up and these movements back and forth between 
disease states are all incorporated in the estimation of the model. Multistate Markov 
models can provide a better clinical understanding of the disease process since the 
information from the entire course of the disease is used to estimate the parameters of the 
model. These models have been used in numerous clinical applications including: 




This approach has not been used before for mRS data and therefore, in this article a 
simulation study is performed to examine the operating characteristics of the proposed 
approach. 
3.2.1 Multistate Markov Models 
The use of multistate Markov modeling requires that the Markov property holds for the 
observed data. Consider a stochastic process with a finite state-space {1,2,3,... }S I , 
where I  represents the number of states in the model. Let ( )X s  be the state occupied at 
time s . The series of observations has the Markov property if the conditional distribution 
of ( )X s t , given 
( )F { ( ) : }X s X v v s  , where ( )FX s  denotes all of the information 
pertaining to the history of X  up to time s [64], satisfies 
    ( )Pr ( ) | F , ( ) Pr ( ) | ( ) ( , ), ,X s ijX s t j X s i X s t j X s i p s t i j I         .  (3.1) 
In other words, a Markov process is one such that the conditional probability distribution 
of the state of a process at a given time is dependent only on the immediately preceding 
observation and not on the earlier ones.   
 Markov models may be defined for discrete time as well as continuous. Although 
the course of disease is a continuous process, clinical trials often only collect data at 
intermittent follow-up visits. In the context of stroke, the exact time of progression or 
recovery, or change of state, of disease is not observed. Data of this type, representative 
of a continuous process that is only observed at discrete time points, is known as panel 
data [72]. Both discrete and continuous time multistate Markov models can be used to 




been adapted for panel data is preferred over a discrete model [68]. In many acute stroke 
trials, the mRS is collected at follow-up visits that are not evenly spaced. In such 
instances, continuous time models are appropriate. A continuous model for panel data can 
only be used in cases where the sampling times are considered to be non-informative [4]. 
An example of non-informative sampling is a fixed observation scheme, where the 
interval of follow-up is specified in advance. However if observations are not fixed or 
random and are self-selected by the subject (informative), this modeling technique is not 
appropriate without properly adjusting for the additional information [4]. For instance, 
these models cannot be used in a scenario where observations occur when a subject visits 
a doctor because they are in poor-condition. A model that incorporates the information 
from the sampling times must be used for this type of self-selected follow-up outcome 
data. In acute stroke trials, the follow-up visits are usually specified in advance and are 
non-informative so continuous modeling is appropriate. 
 A common assumption when fitting continuous-time Markov models is the time-
homogeneity assumption. This is the assumption that the transition probabilities remain 
constant over time. When time-homogeneity is assumed, the probability that the next 
move of the process is from state i  to state j  can be written, 
 { ( ) | ( ) } { ( ) | (0)} ( )ijP X s t j X s i P X t j X p t      .  (3.2) 
Thus, the probabilities only depend on the length of the time interval, t . The ( )ijp t  are 
elements of the transition probability matrix, P(t) . The th( , )i j  entry of P(t)  is the 




 The movement of a subject between states is described by 




( ( ) | (0) )
limij
t






 .  (3.3) 
The intensities represent the instantaneous rate of moving from state i  to state j i . The 
intensities form the generator matrix, Λ , whose rows sum to zero and the diagonal 




  . P(t)  can be solved by taking a matrix exponential of Λ  scaled 












P(t)   (3.4) 
where kΛ  is the k
th
 power of the generator matrix Λ .    
 Suppose now that we observe X  over 1 2 ... Mt t t   . Let 1 2, , ..., Mi i i be the 
observed states over these time points. Then, the associated likelihood function is  
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   (3.6) 
where 
1i
P  is the initial probability that the process is at 1i .  
 The effects of covariates can also be investigated by modeling the intensity as a 
function of the variables of interest, z(t) . The transition intensity matrix elements 
ij  are 
replaced by 







z t   (3.7) 
where (0)
ij  represent the baseline intensities (without covariates) and ij  are the effect of 
covariates on the transition from state i  to state j [4]. To determine the significance of 
a covariate, a likelihood ratio test is used to compare nested models. In Section 3.3, the 
model including treatment is compared to a model without treatment. Thus, the resulting 
intensities are 
 
( )(0) ij z t
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
    (3.8) 
where (0)
ij  represent the intensities without the covariate and ( )z t  is the treatment 
assignment (0 for control and 1 for treatment) for subject n . Thus, the null and 
alternative hypotheses for the test of the effect of treatment are  
0
1
: 0  for all ,










The null hypothesis will be rejected using the asymptotic distribution of 0 12ln( / )L L  




maximum value of the likelihood of the full model. For large n , this asymptotic 
distribution is a 2  with k  degrees of freedom, where k  is the difference in the 
number of parameters in the two models. 
 The difficult part in this process is obtaining the maximum likelihood estimates. 
Often methods such as Newton-Raphson can cause issues because the computation of the 
second derivative can be costly in terms of time. Additionally, if the Hessian matrix is 
non-negative definite away from the optimum, slow or non-convergence may occur. To 
avoid this, other approaches have been proposed. The Broyden-Fletcher-Goldfarb-
Shanno (BFGS) method is used to maximize the likelihood with analytic gradients and 
can be used with or without analytic first derivatives [4, 68]. The BFGS algorithm 
approximates Newton’s iterative method for finding the roots of differentiable functions 
[73]. In this algorithm, the Hessian matrix of second derivatives is not evaluated directly. 
Instead, it approximates the Hessian using gradients. If too many transitions are 
considered with not enough data in a multistate model, the maximum likelihood estimate 
could lie on boundary of the parameter space (when one or more transition intensities 
equal 0). If this occurs, the maximum likelihood estimate may be inconsistent since 
asymptotic theory requires the assumption that the true parameter value lies away from 
the boundary.  
 It is important to consider which transitions can realistically occur in continuous 
time. When the states represent levels of disease severity it is assumed that in order for a 
subject to travel from one state to a non-adjacent state, the subject also had to travel 




transition intensity matrix where non-adjacent state transition intensities are fixed to 
equal zero should be assumed. The exception is with mRS = 6, we assume that death can 
occur from any state and transitions cannot occur out of it because it is an absorbing state. 
The allowable transitions are displayed in Figure 3.1.  
 
Figure 3.1: Multistate model for panel observed mRS data. 
3.2.2 Simulation Scenarios 
In this section, the procedures for examining the operating characteristics of multistate 
Markov models under a variety of conditions are described. First, whether or not the 
multistate Markov model preserves the type I error probability is examined through 
simulations. Next, given the type I error probability, the desired power is examined for 
two clinically relevant scenarios, each with two sets of follow-up trajectories for each of 
the models. The power of the multistate Markov model is compared with that of repeated 
logistic regression. The motivating example of this simulation study is the limited non- 
adjacent state transitions observed in mRS data. The simulation scenarios are generated 




possible. Data from three different phase III acute stroke trials were considered when 
assigning transition probabilities. 
 The first trial used is the National Institute of Neurologic Disorders and Stroke 
(NINDS) tissue-Plasminogen Activator (t-PA) study [38]. The NINDS t-PA trial 
compared t-PA versus placebo in subjects with acute ischemic stroke. The primary 
analysis showed a significant global test score for four (Barthel Index, mRS, Glasgow 
Outcome Scale, and NIHSS) outcomes as well as for the mRS alone [39]. To further 
illustrate the structure of acute stroke trial data, the mRS scores for the control and 
treatment groups are displayed in Sankey plots in Figures 3.2 and 3.3 [74], respectively. 
The Sankey plots allow for a visualization of changes within each treatment group over 
time. The longitudinal bar chart shows the percentage of subjects with each mRS score at 
each follow-up visit. In addition, the wavy lines between each bar, the links, describe the 
change in the number of subjects in each state, over time. A thick line indicates that a 
large number of subjects transition between two states. Note that as illustrated in Table 
3.2 with the mock data, the percentage of transitions that occur between non-adjacent 
states is small.  
 The other two trials considered for data generation were the albumin in acute 
stroke (ALIAS) II trial and the Interventional Management of Stroke (IMS) III trial [43, 
75]. ALIAS II was designed to compare 25% human serum albumin and saline in patients 
with acute ischemic stroke. IMS III was designed to compare intravenous t-PA plus an 
intra-arterial device therapy and/or additional intra-arterial t-PA versus t-PA alone. Both 





Figure 3.2: Sankey plot of NINDS t-pa control group subjects over time. 
 




 For each of the previously mentioned trials, the observed transition counts for 
each follow-up visit are combined in one table to calculate aggregate observed transition 
probabilities. To illustrate, data in Table 3.2 would be combined in an aggregate table 
with 192 (84 + 108) instances where a subject stayed in state 0 out of the total 254 (110 + 
144) instances where a subject started in state 0. Thus, for example, the observed 
aggregate transition probability of remaining in state 0 is 0.76 (192/254), in the mock 
trial. These observed transition probability matrices are calculated for each study to 
illustrate the structure for mRS outcome data from acute stroke trials. As previously 
mentioned, the notable characteristic of the mRS outcome data from these trials is the 
limited number of non-adjacent state transitions. 
 To evaluate power, data are generated under the alternative hypothesis that a 
treatment effect exists. In each multistate Markov model, multiple parameters describe a 
single covariate effect. Therefore, there are many ways in which a significant treatment 
effect could exist. In order to simplify, we consider two different clinically relevant 
scenarios. The first scenario considers a case where only one of the assigned transition 
probabilities differs between the control and treatment groups. For this set of simulations, 
the transition probabilities are assigned such that they are all the same for both groups 
except for the transition from mRS = 3 to mRS = 2 (as well as the transition from mRS = 
2 to 1, mRS = 2 to 0, and mRS = 1 to 0, as the intermediate transitions may not be 
observed). The second scenario for sample size estimation is one where the treatment 




the treatment group, making them more likely. The negative transitions are assigned a 
larger probability in the control group. 
 It is likely that other ordinal scales collected over time have a longitudinal 
structure similar to the mRS, where non-adjacent state transitions are sparse. In order to 
consider scales with differing numbers of states, we used the data generated to mimic the 
mRS described above and collapsed the estimated transition probability matrices to create 
six-, five-, and four-state models. The method in which the states are aggregated is 
described in Table 3.3.  
Table 3.3. Simulation scenarios for power. 
  Number of subjects per group 
States Visits One differing transition All differing transitions 
7 3 400, 500, 600, 800, 1000 300, 400, 500, 600, 800, 1000 
 6 200, 300, 400, 500, 600 125, 150, 175, 200, 300, 400 
6 3 400, 500, 600, 800, 1000 300, 400, 500, 600, 800, 1000 
 6 150, 200, 300, 400, 500, 600 125, 150, 175, 200, 300, 400 
5 3 300, 400, 500, 600, 800, 1000 200, 300, 400, 500, 600, 800, 1000 
 6 100, 150, 200, 300, 400, 500, 600 75, 100, 125, 150, 175, 200, 300, 
400 
4 3 200, 300, 400, 500, 600, 800, 1000 200, 300, 400, 500, 600, 800, 1000 
 6 100, 150, 200, 300, 400, 500, 600 50, 75, 100, 125, 150, 175, 200, 
300, 400 
3 3 200, 300, 400, 500, 600, 800, 1000 200, 300, 400, 500, 600, 800, 1000 
 6 100, 150, 200, 300, 400, 500, 600 50, 75, 100, 125, 150, 175, 200, 
300, 400 
 
 In practice, collapsing states is a decision that should be made with caution. For 
example, if there is clinical evidence that two health states are not distinct, it may be 
acceptable to combine them. If two health states are aggregated that are vastly different 
there could be a loss of power. In order to illustrate this point, for the 5-state (and 




where only the transition from mRS = 3 to mRS = 2 differs, there is an expected loss in 
power for these aggregated models. Thus, in the case where only one transition differs, an 
additional scenario was considered where mRS = 2 and mRS = 3 are not combined, 
referred to as the 5-state* model.  
 The probabilities used to assign outcome trajectories are listed in Appendices 3A-
3C. Using these probabilities, the data generation includes the following steps: 
1. Generate a sample of treatment assignments from a random uniform(0, 1) 
distribution where the probability that the thm  subject is assigned to treatment is 
0.5. 
2. Generate random uniform variables for all t . 
3. Assign a state for 0t   using the probabilities described in the appendices. 
4. For each 0t   use the probabilities to assign a state conditional on the state 
occupied at 1t  . 
 To determine the type I error, data are generated under the null hypothesis of no 
treatment effect. The simulation scenarios for estimation of type I error include differing 
number of states and increasing sample size per group, starting at 200. 
 The simulation studies for power are repeated for each set of simulation 
parameters (Table 3.4) allowing the number of subjects in each treatment group to vary, 
as well as the number of follow-up visits (three or six visits). Each set of simulations is 
carried out using 1,000 runs. For each set of parameters the sample size is set to observe 




observed value from the previously described simulations. The resulting power is 
compared to that of the repeated logistic regression model.  
Table 3.4. Modified Rankin Scale inclusion categories. 
Symbol Model mRS Scores 
 7 state mRS 0, mRS 1, mRS 2, mRS 3, mRS4, mRS 5, mRS 6 
 6 state mRS 0, mRS 1, mRS 2, mRS 3, mRS4, mRS 5-6 
 5 state mRS 0, mRS 1, mRS 2, mRS 3, mRS 4-6 
 4 state mRS 0, mRS 1, mRS 2-3, mRS 4-6 
 3 state mRS 0-1, mRS 2-3, mRS 4-6 
 
 The data used were simulated using SAS 9.4 statistical software. SAS 9.4 was 
also used to run the Generalized Estimating Equation models for repeated measures 
logistic regression with PROC GENMOD. The Markov models were fitted in R statistical 
software version 3.3.0 using the ‘msm’ package for multistate Markov models [4]. 
3.3 Results 
In this section, the behavior of the type I error and power is evaluated. The simulation 
results of the type I error are displayed in Figure 3.4. For the application considered, with 
data structured similar to the three acute stroke trials described in Section 3.2, the type I 
error probability is preserved for all of the multistate Markov models. In order to examine 
whether the chi-square approximation of the likelihood ratio test is appropriate for 
comparing the nested models, p-values under the appropriate chi-square distribution were 
obtained and are shown in Appendix 3D. The p-values appear to be approximately 
uniform and the test-statistic sampling distribution approximates the chi-square 





Figure 3.4: Graph of approximated type I error probabilities for models with three follow-up visits based on 
1,000 simulations. 
 
 For considering power we need to set alternative hypotheses. There are many 
potential alternative hypotheses so we consider two scenarios that are clinically relevant. 
In the first scenario, transition probabilities are assigned such that the only difference 
between treatment groups is in the transition from mRS = 3 to mRS = 2. The results with 
three and six follow-up visits are displayed in Figures 3.5a and 3.5b, respectively. The 
transition probabilities assigned for these simulations are presented in Appendix 3B. The 
results indicate that for a seven-state model with three follow-up visits, approximately 
500 subjects are needed in each group to obtain 80% power. There is a marginal increase 
in power when states mRS = 4 and mRS = 5 are combined in the six-state model. When 




decrease in power. This is expected because the model was misspecified. The only 
difference between treatment groups was in the transition from mRS = 3 to mRS = 2 so 
when these two states are combined, there are virtually no differences to detect. The same 
phenomenon is observed in the four-state model because the difference is still lost from 
aggregating mRS = 2 and mRS = 3. If we consider the fact that the difference lies 
between those two states and instead collapse mRS = 0 and mRS = 1 in the alternative 
five-state model (5*) then we see another marginal increase in power. The observed 
increases in power are expected because there are no differences in the two groups in the 
aggregated states and there are fewer parameters to estimate in the model.  
 Figure 3.5b displays the approximated power in the scenario where only the 
transition from mRS = 3 to mRS = 2 differs, now with six follow-up visits instead of 
three. The results for the models with six follow-up visits are similar to those in the 
models with three follow-up visits, except that the power is significantly increased. The 
power for the seven-, six- and five-state* model are all very similar. Each of these models 
requires approximately 150 subjects in each group to obtain 80% power. When mRS = 2 
and mRS = 3 are combined in the five-state model (and subsequently in the four-state 
model), there is an extreme loss of power, as previously observed.  
 The results of the power simulations in the second scenario, where the treatment 
effect exists for all transitions, are displayed in Figures 3.5c and 3.5d. The assumed 
transition probabilities are described in Appendix 3C. The approximate power for the 
three follow-up visit case is displayed in Figure 3.5c. In the six- and seven- state model, 




There are negligible differences in power between each of the models. Since there are 
differences in all transitions, there will be some loss of power by aggregating states. 
However, there is a gain in power with fewer parameters in a reduced model. These two 
facts lead to very minimal change in power. For any given model with three follow-up 
visits in this scenario, approximately 600 subjects are needed per group to attain 80% 
power. 
 
Figure 3.5: Graph of approximated power based on 1,000 simulations. 
 
 Figure 3.5d displays the approximated power where all assumed transition 
probabilities differ between groups and the number of follow-up visits is increased from 




up visits are similar to those from the models with three follow-up visits, with a 
significant increase in power. The increase in power is expected since there are twice as 
many observation per subject contributing to the estimation of the model parameters. In 
this case, approximately 250 subjects are needed per group to reach 80% power. 
Table 3.5. Comparison of power for models with three follow-up visits. 
    







Elteren 7-state 6-state 5-state 4-state 3-state 
2 to 1 only 200 0.257 0.117 - - - 0.206 0.256 
 
300 0.371 0.138 - - 0.544 0.283 0.349 
 
400 0.469 0.193 0.635 0.663 0.670 0.381 0.468 
 
500 0.573 0.222 0.753 0.771 0.787 0.499 0.544 
 
600 0.646 0.224 0.837 0.848 0.870 0.567 0.626 
 
800 0.743 0.267 0.926 0.939 0.956 0.703 0.760 
 
1000 0.853 0.334 0.974 0.981 0.989 0.815 0.868 
         All shifts 200 0.735 0.741 - - 0.405 0.358 0.470 
 
300 0.893 0.898 0.582 0.629 0.563 0.508 0.643 
 
400 0.960 0.970 0.694 0.763 0.723 0.615 0.765 
 
500 0.988 0.983 0.811 0.863 0.811 0.733 0.879 
 
600 0.996 0.997 0.875 0.943 0.897 0.814 0.933 
 
800 1.000 1.000 0.961 0.982 0.971 0.911 0.977 
 
1000 1.000 1.000 0.989 0.998 0.990 0.975 0.996 
 
 The approximated power from the models displayed in Figure 3.5 is compared 
with that from repeated logistic regression in Tables 3.5 and 3.6. Table 3.5 lists the power 
for the models with three follow-up visits and Table 3.6 lists the power for the models 
with six follow-up visits. Repeated logistic regression was performed using the 
dichotomized mRS scores, where scores of 0 or 1 were defined as successes and scores 




Table 3.6. Comparison of power for models with six follow-up visits. 
    







Elteren 7-state 6-state 5-state 4-state 3-state 
2 to 1 only 100 0.119 0.075 - - 0.474 0.288 0.321 
 
150 0.188 0.098 - 0.622 0.629 0.417 0.463 
 
200 0.257 0.117 0.732 0.734 0.776 0.546 0.578 
 
300 0.371 0.138 0.871 0.889 0.920 0.714 0.784 
 
400 0.469 0.193 0.957 0.961 0.967 0.860 0.906 
 
500 0.573 0.222 0.983 0.990 0.991 0.936 0.947 
 
600 0.646 0.224 0.994 0.992 1.000 0.997 0.982 
         All shifts 50 0.246 0.241 - - - 0.210 0.326 
 
75 0.350 0.357 - - 0.419 0.358 0.485 
 
100 0.463 0.476 - - 0.540 0.434 0.584 
 
125 0.523 0.519 0.579 0.673 0.659 0.521 0.725 
 
150 0.602 0.642 0.688 0.754 0.732 0.598 0.806 
 
175 0.687 0.690 0.735 0.827 0.794 0.662 0.867 
 
200 0.735 0.741 0.809 0.901 0.847 0.751 0.915 
 
300 0.893 0.898 0.945 0.975 0.968 0.906 0.984 
 
400 0.960 0.970 0.985 0.994 0.992 0.981 0.997 
 
 When only one assigned transition probability differs between groups, in correctly 
specified models, the multistate Markov model requires significantly fewer subjects than 
the repeated logistic regression model to be adequately powered. When the multistate 
model is misspecified, the repeated logistic regression is more powerful. When all 
assumed transition probabilities differ between groups, the repeated logistic regression 
requires fewer subjects per group to reach 80% power. When there are three follow-up 
visits, the repeated logistic regression model only requires about 300 subjects per group 




visit case, approximately 150 subjects are needed per group compared to 250 in the 
multistate Markov model. 
3.4  Summary and Discussion 
The mRS, one of the most commonly used outcome measures in acute stroke trials, is 
ordinal but is often dichotomized for analysis. The loss of information from 
dichotomizing the ordinal variable was examined in this article. In addition, despite the 
availability of multiple mRS scores over time in many trials, a single measurement is 
often chosen for primary analysis. The additional information available from the 
longitudinal data could add further efficiency to the analysis. Multistate Markov 
modeling is presented here as an alternative analytic approach for ordinal outcomes 
collected longitudinally. The multistate Markov model describes how a process moves 
between states over time, which is desirable because it lends itself to clinically relevant 
interpretations.  
 In this paper, we have considered time-homogenous continuous Markov 
multistate models for mRS outcome data observed in phase III acute stroke trials. 
Simulations demonstrated that the desired type I error probability is preserved for the 
likelihood ratio test comparing a multistate Markov model including treatment to one 
without. Power was examined for two different clinically relevant scenarios. The two 
scenarios represented two diverse instances where a treatment effect exists. In the first 
scenario all of the assigned transition probabilities were the same for the two treatment 




probabilities in the second scenario differed between the groups for all transitions, 
representing a positive treatment effect for all shifts. 
 The key findings of the simulation studies could be summarized as follows: 
 When the only difference between the treatment groups in assigned transition 
probabilities is from mRS = 3 to mRS =2,  
o misspecification of the five-state (and four-state) multistate model 
drastically decreases power as this masks the only difference between 
groups, the transition from mRS = 3 to mRS = 2  
o the multistate model yielding the highest power is the 5-state* model 
where mRS = 4 and mRS = 5 are combined, as well as mRS = 0 and mRS 
= 1 
o power is not drastically different for the seven- six- or five-state* Markov 
model 
o the multistate model, when correctly specified, is more powerful than 
repeated logistic regression 
 When all assigned transition probabilities differ between groups, 
o power is essentially equal for all four multistate Markov models 
considered 
o the repeated logistic regression models are more powerful than the 
multistate Markov models 
 For both scenarios, and all combinations of states considered, increasing the 




 We considered a case where two distinct states were combined to examine the 
effects of misspecification. It is important to note that for a process that is truly Markov 
on I  states, a reduced-state model will not satisfy the Markov property [76]. The 
sojourn time will be non-exponential for the merged states and bias can be expected 
through the misspecification. This highlights the importance of correctly specifying 
models when using the multistate Markov approach. A modified version of Akaike’s 
criterion could aid in model selection [77].  
 We conclude that multistate Markov modeling can be a more efficient approach to 
analysis of mRS data from acute stroke trials. There are situations where dichotomization 
might not lose efficiency and may be more powerful than the multistate Markov model. 
Depending on the observed data structure, either technique could be more powerful. In 
every model, however, increasing the number of follow-up visits from three to six 
dramatically improved the power to detect a treatment difference.  
 A limitation of this study is the computational intensity required to run the 
simulations. For the scenarios with a larger number of states, the time required to 
complete the simulations was lengthy. Because of the time these simulations take, each 
was only repeated 1,000 times. Larger simulation studies, say with 10,000 runs rather 
than 1,000, would improve the precision on the estimates of the operating characteristics. 
A second limitation of this study is the lack of effect size measurement. In order to 
quantify an effect size, we would need to be able to define what outcome would be of 
interest. For example, some previous studies have considered a 10% difference in 




scale. Quantification of the effect is not straightforward when using Markov multistate 
modeling. This is a practical question to consider in the future.  
 A future direction of this work could be to compare the results of multistate 
Markov modeling to repeated cumulative logistic regression. At the time of submission 
the authors could not find any publications where longitudinal proportional odds models 
or adjacent categories logit models were applied to mRS data. Interesting issues arise 
about how to handle the proportional odds assumption and how to compare models when 
the assumption fails. This may be a useful extension of the analysis of longitudinal mRS 






Appendix 3A: assumed transition probabilities for type I error simulations 
 
In this appendix, we present Tables 3.1A-3.4A, which show the probabilities used to 
determine the trajectories for the subjects in the type I error simulation study. 
Table 3.1A. Assumed transition probabilities for the seven-state model. 
 Probabilities for time = 1 
 0 1 2 3 4 5 6 
 0.1000 0.1200 0.1300 0.1500 0.2300 0.1400 0.1300 
 
Conditional Transition Probabilities for time > 1 
 0 1 2 3 4 5 6 
0 0.8000 0.1700 0.0200 0.0050 0.0030 0.0010 0.0010 
1 0.2000 0.6800 0.0800 0.0200 0.0100 0.0050 0.0050 
2 0.0500 0.2800 0.5400 0.1100 0.0100 0.0010 0.0090 
3 0.0200 0.0800 0.2200 0.6000 0.0600 0.0050 0.0150 
4 0.0050 0.0150 0.0600 0.2300 0.6000 0.0700 0.0200 
5 0.0005 0.0070 0.0075 0.0450 0.2800 0.4800 0.1800 
 
Table 3.2A. Assumed transition probabilities for  
the six-state model. 
 Probabilities for time = 1 
 0 1 2 3 4/5 6 
 0.100 0.120 0.130 0.150 0.370 0.130 
       
Conditional Transition Probabilities for time > 1 
 0 1 2 3 4/5 6 
0 0.800 0.170 0.020 0.005 0.004 0.001 
1 0.200 0.680 0.080 0.020 0.015 0.005 
2 0.050 0.280 0.540 0.110 0.011 0.009 
3 0.020 0.080 0.220 0.600 0.065 0.015 






Table 3.3A. Assumed transition probabilities for  
the five-state model. 
 Probabilities for time = 1 
 0 1 2/3 4/5 6 
 0.100 0.120 0.280 0.370 0.130 
      
Conditional Transition Probabilities for time > 1 
 0 1 2/3 4/5 6 
0 0.800 0.170 0.025 0.004 0.001 
1 0.200 0.680 0.100 0.015 0.005 
2/3 0.035 0.180 0.735 0.038 0.012 
4/5 0.003 0.011 0.172 0.714 0.100 
 
Table 3.4A. Assumed transition probabilities for  
the four-state model. 
 Probabilities for time = 1 
 0/1 2/3 4/5 6 
 0.220 0.280 0.370 0.130 
 
Conditional Transition Probabilities for time > 1 
 0/1 2/3 4/5 6 
0/1 0.924 0.063 0.010 0.003 
2/3 0.215 0.735 0.038 0.012 









Appendix 3B: assumed transition probabilities for the scenario with only one differing assumed transition  
 
In this appendix, we present Tables 3.1B-3.4B, which show the probabilities used to determine the trajectories for the subjects 
in the simulation study to approximate power when the treatment effect exists for only one transition (from mRS = 3 to mRS = 
2).  
 
Table 3.1B. Assumed transition probabilities for the seven-state model. 
 Probabilities for time = 1 (control) 
 0 1 2 3 4 5 6 
 0.110 (0.090) 0.130 (0.110) 0.150 (0.110) 0.110 (0.190) 0.230 (0.230) 0.140 (0.140) 0.130 (0.130) 
 
Conditional transition probabilities for time > 1 (control) 
 0 1 2 3 4 5 6 
0 0.800 (0.800) 0.170 (0.170) 0.020 (0.020) 0.005 (0.005) 0.003 (0.003) 0.001 (0.001) 0.001 (0.001) 
1 0.200 (0.200) 0.680 (0.680) 0.080 (0.080) 0.020 (0.020) 0.010 (0.010) 0.005 (0.005) 0.005 (0.005) 
2 0.050 (0.050) 0.280 (0.280) 0.540 (0.540) 0.110 (0.110) 0.010 (0.010) 0.001 (0.001) 0.009 (0.009) 
3 0.030 (0.010) 0.110 (0.050) 0.300 (0.140) 0.480 (0.720) 0.060 (0.060) 0.005 (0.005) 0.015 (0.015) 
4 0.005 (0.005) 0.015 (0.015) 0.060 (0.060) 0.230 (0.230) 0.600 (0.600) 0.070 (0.070) 0.020 (0.020) 







Table 3.2B. Assumed transition probabilities for the six-state model. 
 Probabilities for time = 1 (control) 
 0 1 2 3 4/5 6 
 0.110 (0.090) 0.130 (0.110) 0.150 (0.110) 0.110 (0.190) 0.370 (0.370) 0.130 (0.130) 
 
Conditional transition probabilities for time > 1 (control) 
 0 1 2 3 4/5 6 
0 0.800 (0.800) 0.170 (0.170) 0.020 (0.020) 0.005 (0.005) 0.004 (0.004) 0.001 (0.001) 
1 0.200 (0.200) 0.680 (0.680) 0.080 (0.080) 0.020 (0.020) 0.015 (0.015) 0.005 (0.005) 
2 0.050 (0.050) 0.280 (0.280) 0.540 (0.540) 0.110 (0.110) 0.011 (0.011) 0.009 (0.009) 
3 0.030 (0.010) 0.110 (0.050) 0.300 (0.140) 0.480 (0.720) 0.065 (0.065) 0.015 (0.015) 
4/5 0.003 (0.003) 0.011 (0.011) 0.034 (0.034) 0.138 (0.138) 0.714 (0.714) 0.100 (0.100) 
 
 
Table 3.3B. Assumed transition probabilities for the five-state model. 
 Probabilities for time = 1 (control) 
 0 1 2/3 4/5 6 
 0.110 (0.090) 0.130 (0.110) 0.260 (.300) 0.370 (.370) 0.130 (0.130) 
 
Conditional transition probabilities for time > 1 (control) 
 0 1 2/3 4/5 6 
0 0.800 (0.800) 0.170 (0.170) 0.025 (0.025) 0.004 (0.004) 0.001 (0.001) 
1 0.200 (0.200) 0.680 (0.680) 0.100 (0.100) 0.015 (0.015) 0.005 (0.005) 
2/3 0.040 (0.030) 0.195 (0.165) 0.715 (0.755) 0.038 (0.038) 0.012 (0.012) 









Table 3.4B. Assumed transition probabilities for the four-state model. 
 Probabilities for time = 1 (control) 
 0/1 2/3 4/5 6 
 0.120 (0.100) 0.150 (0.120) 0.230 (0.280) 0.500 (0.500) 
 
Conditional transition probabilities for time > 1 (control) 
 0/1 2/3 4/5 6 
0/1 0.924 (0.924) 0.063 (0.063) 0.010 (0.010) 0.003 (0.003) 
2/3 0.235 (0.195) 0.715 (0.755) 0.038 (0.038) 0.012 (0.012) 









Appendix 3C: assumed transition probabilities for scenario with global treatment effect\ 
 
In this appendix, we present Tables 3.1C-3.4C, which show the probabilities used to determine the trajectories for the subjects 
in the simulation study to approximate power when the treatment effect exists for all transitions. 
Table 3.1C. Assumed transition probabilities for the seven-state model. 
 Probabilities for time = 1 (control) 
 0 1 2 3 4 5 6 
 0.150 (0.100) 0.150 (0.100) 0.140 (0.100) 0.100 (0.150) 0.200 (0.250) 0.200 (0.230) 0.050 (0.070) 
 
Conditional transition probabilities for time > 1 (control) 
 0 1 2 3 4 5 6 
0 0.800 (0.720) 0.186 (0.230) 0.010 (0.042) 0.001 (0.002) 0.001 (0.002) 0.001 (0.002) 0.001 (0.002) 
1 0.200 (0.160) 0.693 (0.676) 0.080 (0.120) 0.001 (0.002) 0.005 (0.010) 0.001 (0.002) 0.020 (0.030) 
2 0.050 (0.030) 0.280 (0.220) 0.509 (0.528) 0.100 (0.140) 0.020 (0.030) 0.001 (0.002) 0.040 (0.050) 
3 0.020 (0.010) 0.130 (0.080) 0.230 (0.200) 0.560 (0.620) 0.040 (0.050) 0.010 (0.020) 0.010 (0.020) 
4 0.010 (0.005) 0.030 (0.020) 0.060 (0.050) 0.250 (0.200) 0.510 (0.565) 0.070 (0.080) 0.070 (0.080) 

















Table 3.2C. Assumed transition probabilities for the six-state model. 
 Probabilities for time = 1 (control) 
 0 1 2 3 4/5 6 
 0.150 (0.100) 0.150 (0.100) 0.140 (0.100) 0.100 (0.150) 0.400 (0.480) 0.060 (0.070) 
 
Conditional transition probabilities for time > 1 (control) 
 0 1 2 3 4/5 6 
0 0.800 (0.720) 0.186 (0.230) 0.010 (0.042) 0.001 (0.002) 0.002 (0.004) 0.001 (0.002) 
1 0.200 (0.160) 0.693 (0.676) 0.080 (0.120) 0.001 (0.002) 0.006 (0.012) 0.020 (0.030) 
2 0.050 (0.030) 0.280 (0.220) 0.509 (0.528) 0.100 (0.140) 0.021 (0.032) 0.040 (0.050) 
3 0.020 (0.010) 0.130 (0.080) 0.230 (0.200) 0.560 (0.620) 0.050 (0.070) 0.010 (0.020) 
4/5 0.006 (0.003) 0.020 (0.013) 0.035 (0.028) 0.160 (0.125) 0.619 (0.641) 0.160 (0.190) 
 
 
Table 3.3C. Assumed transition probabilities for the five-state model. 
 Probabilities for time = 1 (control) 
 0 1 2/3 4/5 6 
 0.150 (0.100) 0.150 (0.100) 0.240 (0.250) 0.400 (0.480) 0.060 (0.070) 
 
Conditional transition probabilities for time > 1 (control) 
 0 1 2/3 4/5 6 
0 0.800 (0.720) 0.186 (0.230) 0.011 (0.044) 0.002 (0.004) 0.001 (0.002) 
1 0.200 (0.160) 0.693 (0.676) 0.081 (0.122) 0.006 (0.012) 0.020 (0.030) 
2/3 0.035 (0.020) 0.205 (0.150) 0.700 (0.745) 0.035 (0.050) 0.025 (0.035) 









Table 3.4C. Assumed transition probabilities for the four-state model. 
 Probabilities for time = 1 (control) 
 0/1 2/3 4/5 6 
 0.300 (0.200) 0.240 (0.250) 0.400 (0.480) 0.060 (0.070) 
 
Conditional transition probabilities for time > 1 (control) 
 0/1 2/3 4/5 6 
0/1 0.939 (0.893) 0.046 (0.083) 0.004 (0.008) 0.011 (0.016) 
2/3 0.240 (0.170) 0.700 (0.745) 0.035 (0.050) 0.025 (0.035) 
4/5 0.026 (0.016) 0.195 (0.153) 0.619 (0.641) 0.160 (0.190) 
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Appendix 3D: plots of p-values and test-statistics from type I error simulation study 
 
In this appendix, we present Figures 3.1D and 3.2D, which display the distribution of the 
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Abstract 
In clinical trials, longitudinally assessed ordinal outcomes are commonly dichotomized 
and only the final measure is used for primary analysis, partly for ease of clinical 
interpretation. Dichotomization of the ordinal scale and failure to utilize the repeated 
measures can reduce statistical power. Additionally, in a certain emergent settings, the 
same measure cannot be assessed at baseline prior to treatment. For such a data set, a 
piecewise-constant multistate Markov model that incorporates a latent model for the 
unobserved baseline measure is proposed. These models can be useful in analyzing 
disease history data and are advantageous in clinical applications where a disease process 




acute stroke clinical trials data. Conclusions drawn in this paper are consistent with those 
from the primary analysis for treatment effect in both of the motivating examples. Use of 
these models allows for a more refined examination of treatment effect and describes the 
movement between health states from baseline to follow-up visits which may provide 
more clinical insight into the treatment effect. 
Keywords 










Outcomes on an ordinal scale is quite common in clinical trials [78]. It is also common in 
these trials to analyze the data using a dichotomized version of the ordinal measure. For 
instance, in treatments of acute stroke, often the modified Rankin Scale (mRS) is used as 
the primary outcome. The mRS measures functional ability using a 7-point ordinal scale 
(Table 4.1). Although, mRS is measured on this 7-point scale, for testing primary 
hypotheses of interest, it is commonly dichotomized either by collapsing into {0,1}  vs 
{2,3,4,5,6} or {0,1,2}  vs {3,4,5,6} . Loss of information, when such ordinal outcomes 
are collapsed into a dichotomy, has been studied and shown to result in reduction of 
statistical power [79]. In stroke trials, alternative analytic methods on the observed 
ordinal scale are gaining attention [1].  
Table 4.1. Modified Rankin Scale. 
Score Description 
0 No symptoms at all 
1 
No significant disability despite symptoms; able to carry out all usual duties and 
activities 
2 
Slight disability; unable to carry out all previous activities but able to look after 
own affairs without assistance 
3 Moderate disability requiring some help, but able to walk without assistance 
4 
Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 
5 




 Another common approach in most longitudinal trials that measure mRS over 




because the outcome status at 90 days is considered to be the only measurement of 
clinical relevance. Moreover, typically, the ultimate goal of a treatment or therapeutic 
action is to achieve improvement in patient health compared to their baseline measure. To 
accurately quantify improvement, a measure of the outcome at baseline would be ideal. 
Conditions with sudden onset, such as traumatic brain injury, stroke and status epilepticus 
often require immediate attention and treatment, posing a challenge to assess baseline 
outcome measures for clinical trials that may also lack practical meaning based on patient 
status. Specific to acute stroke trials the mRS is not obtainable at baseline [80]. The 
current method of addressing this is to adjust for the severity of the condition (disease) at 
baseline.  
 In this manuscript a continuous-time non-homogeneous Markov process is 
proposed as an alternative to study the evolution of acute onset diseases. Of specific 
interest is exploration of potential differences in transition rates between two treatment 
groups. Using this method, it is possible to analyze treatment effects in the observed 
ordinal scale and incorporate data measured longitudinally. In addition, after treatment, 
since much of the progression or recovery experienced by acute ischemic stroke patients 
is expected to occur early, on a method for predicting the baseline mRS state is proposed 
[81]. This baseline mRS may then be utilized in a model that more fully characterizes the 
evolution of disease over time. 
 The paper is organized as follows. Two motivating examples of large acute stroke 
therapy trials are described in Section 4.2. Homogeneous and piecewise-constant 




estimation procedure is described and demonstrated and piecewise-constant MSMMs 
using the estimated baseline scores for the motivating examples are fit. Concluding 
remarks are presented in Section 4.4. 
4.2 Methods 
Methods are developed and motivated through two phase III acute stroke therapy trials, 
namely the National Institute of Neurologic Disorders and Stroke tissue plasminogen 
activator (NINDS tPA) Stroke Study Part 2 [38] and the Albumin in Acute Stroke 
(ALIAS) Trial [82].  
 The NINDS tPA Stroke Study Part 2 was designed to compare intravenous tPA 
versus placebo in subjects with acute ischemic stroke using a global test statistic [38]. 
The global test statistic simultaneously tested for treatment effect in four correlated 
outcomes (mRS, Barthel Index, Glasgow outcome scale and National Institutes of Health 
Stroke Scale). The Barthel Index is a simple index of independence that scores the ability 
of patients to care for themselves [40]. Patients that can perform all activities assessed 
with complete independence are given a score of 100. The Glasgow outcome scale is a 
global assessment of function that ranges from 1 indicating good recovery to 5, death 
[41]. The National Institutes of Health Stroke Scale (NIHSS) is a 42-point scale that 
measures neurologic deficit where 0 indicates normal function [83].  
 A total of 624 patients were enrolled in NINDS tPA, with 312 in each treatment 
group. The primary analysis showed a significant global test score for the four 




addition to the primary outcome assessment at 90 days, the mRS was collected at 7-10 
days, 180 days and 360 days from randomization for each subject.  
 The ALIAS Trial was designed to compare 25% human serum albumin and saline 
in patients with acute ischemic stroke [82]. Part 1 of the trial was suspended after 
enrolling 434 subjects due to safety concerns of albumin [84]. Part 2 of the trial was 
slightly redesigned with unblinded safety analysis and enrolled 841 subjects. The analysis 
of both Parts 1 and 2, as well as the two combined, showed a lack of treatment effect on 
primary and secondary outcomes, including the dichotomized mRS at 90 days [85]. In 
addition to the primary outcome assessment at 90 days, the mRS was also collected at 30 
days, 180 days, 270 days and 360 days from randomization for each subject. 
4.2.1 Multistate Markov Models 
MSMMs in continuous-time has been used to model the course of many diseases [4]. The 
MSMMs incorporate longitudinal ordinal data and can provide clinically relevant 
summary statistics to describe covariate effects, including sojourn times and transition 
rates. These models are advantageous in clinical applications, where a disease process 
naturally moves through increasing stages of severity [4]. Homogeneous continuous-time 
MSMMs, where the transition rates are assumed to be constant over time, have been used 
to analyze various diseases [86-88].  
 The assumption of homogeneity is not always realistic. With acute onset diseases, 
the rapid nature of onset and intervention likely characterize a process that changes 
quickly early on and tapers off after the initial acute recovery stage. The transition rates 




movement post-baseline, are likely to differ from those observed in the acute phase. In 
this case, a non-homogeneous model with piecewise constant intensity rates can be used.  
 Multistate Markov modeling requires that the Markov property holds for the 
observed data. Consider a system with a finite state-space {1,2,3,..., }I , where I  
represents the number of states. Let ( )X s t  be a discrete random variable that indicates 
the state occupied by the system at time s t . Let 
( )F { ( ) : }X s X v v s  which denotes all 
information pertaining to the history of X  up to time s  [64]. The series of observations 
has the Markov property if the conditional distribution of ( )X s t given 
( )FX s , satisfies 
    ( )( ) | F , ( ) ( ) | ( ) ( , ), ,X s ijP X s t j X s i P X s t j X s i p s t i j         .  (4.1) 
In other words, the present state depends only on the immediately preceding observation 
and not on the ones before it. In the context of clinical trials, the state of the system is the 
health state of one individual.  
 Though the ordinal outcome in acute therapy clinical trials is observed at discrete 
times, the disease process is continuous, where progression or recovery can occur at any 
time. Continuous-time MSMMs can analyze this type of data, known as panel data, as 
long as the sampling times are considered to be noninformative [4]. In the clinical trial 
setting where the observation scheme is fixed in advance, this assumption is valid. If, 
however, a subject visited a clinic because of a change in symptoms and the outcome was 
collected, the sampling time would be informative and could bias inference. These 




sampling times but also include exact time of death, which is commonly observed in 
clinical trials. 
 A common assumption of continuous-time MSMMs is that of homogeneity, 
where transition probabilities remain constant over time. When homogeneity is assumed, 
the transition probabilities, ( )ijp t , are defined as 
 ( ) { ( ) | ( ) } { ( ) | (0) }ijp t P X s t j X s i P X t j X i       .  (4.2) 
Since this expression does not depend on s , the transition from state i  to state j on a 
time interval of length t  has the same probability at any time. The ( )ijp t  are elements of 
the transition probability matrix, ( )tP . 
 The movement of a subject between states is described by 




( ( ) | (0) )
lim , forij
t







  .  (4.3) 
The intensities represent the instantaneous rate of moving from state i  to state j i  and 





  . The transition probability matrix ( )tP  can be solved by taking a matrix 














P   (4.4) 
where kΛ  is the k
th
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 ,  (4.6) 
where 0iP  is the initial probability that the process is at 0i . 
4.2.2 Piecewise-constant Multistate Markov Models 
In the case of ischemic stroke occurrence and treatment, subjects can get better or worse 
very quickly. For this reason, the time homogeneity assumption is expected to fail for the 
first transition, from the estimated baseline to the first observed outcome. Therefore, 
assumption of homogeneity is relaxed and a non-homogeneous model is considered. 
  The MSMM for panel data can be extended to accommodate piecewise-constant 
intensity matrices for the non-homogeneous case [59]. Here, the transition probability 
functions are dependent on s  and the transition matrix function is ( , ) ( ( , ))ijs t p s tP . The 
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   .  (4.7) 
The time-homogeneity assumption can be tested by using a likelihood ratio test to 
compare the time-homogenous model to piecewise-constant models with different cutoff 
times. 
 The effect of a covariate, specifically treatment, is incorporated into the model as 
transition intensity functions [69]. Let z be a vector of observed covariates then 
 ( ; ) ( )exp( ' ( )), ( ) 0ij ij ij ijt z t z t t       (4.8) 
where ( )ij t  is the parameter vector associated with the covariate vector z  in the 
transition between states i  and j  in time t . The transitional rates are represented by
( ; )ij t z  at time t  for the subjects with vector z . 
4.2.3 Latent Baseline Estimation 
To consider the full evolution of ischemic stroke over time, an estimated baseline 
functional outcome is needed because baseline mRS is not obtainable in the acute setting. 
While functional outcome is not available at baseline, many other measures that are 
correlated with functionality are available. An estimation procedure using baseline 
characteristics known to be highly correlated with the mRS was developed. 
 As a preliminary step, to summarize information from numerous baseline 
measurements considered clinically relevant for functional outcome in ischemic stroke 
patients, data reduction was performed using a Principal Components Analysis (PCA). 




randomization, the Alberta Stroke Program Early CT score (ASPECTS), and NIHSS. 
Age and time from stroke onset to randomization are two very well established predictors 
of outcome in acute stroke. Another baseline characteristic associated with poor outcome 
is “stress” hyperglycemia [89]. This hyperglycemia can be quantified using acute post-
stroke glucose levels. The ASPECTS is also a strong prognostic indicator of outcome 
[90], which is a 10-point quantitative topographic CT scan score, where a normal scan 
receives a score of 10 [91]. For each defined region of the brain, a point is subtracted if 
there is evidence of ischemic change. The NIHSS is commonly used to measure baseline 
stroke severity. The individual items of the scale are presented in Appendix 4A. Baseline 
NIHSS is known to strongly predict outcome in acute stroke therapy trials [92]. Although 
total score is typically used for indicating stroke severity, each item of the scale was used 
in the PCA individually in order to more efficiently assess the contribution of each facet 
of the scale.  
 After reducing the data to fewer PCA’s sextiles (six categories because the 
seventh category, namely mRS = 6 corresponds to death) based on the joint distributions 
of the PCA’s will be used to define the baseline states of the individuals. Then the 
MSMM likelihood ratio tests will be used to compare treatment effects. However, in this 
likelihood ratio test, the uncertainty of the estimated baseline states has to be considered. 
This is achieved through bootstrap approach, using which an empirical distribution was 
derived to determine the p-values. The steps used in this non-parametric bootstrap 
approach are as follows: 




2. Use the baseline estimation procedure from the original data on each of the 1,000 
bootstrapped samples (fixing the number of significant components as well as the 
variables used in each of the component score calculation). 
3. Fit the piecewise MSMM to each resample and obtain the test statistic. 
4. Compare the original test statistic to the new bootstrap distribution, made up of 
the 1,000 test statistics from the bootstrap samples.  
5. The bootstrap p-value is calculated by finding the proportion of bootstrap samples 
in which the test statistics is larger than or equal to the one calculated from the 
original sample. 
4.3 Results 
Detailed descriptions of the PCA for each trial are presented in Appendix 4B. For both 
NINDS tPA and ALIAS, most of the variability was adequately explained by the first two 
components. Thus, component scores were calculated for Components 1 and 2 for each 
trial. Larger values on the component scores were expected to be associated with worse 
functional outcome. To assign the baseline mRS state, each of the component scores were 
divided into sextiles with equal probability. In Figure 4.1, the joint distribution of the two 
discretized scores are shown were used to assign values of mRS = 0 to mRS = 5 with 
equal probability (subjects cannot be dead at baseline, so no one was assigned an mRS = 
6). There is uncertainty in the assignment of baseline states which needs to be accounted 
for in the hypothesis tests comparing treatments. 
 In the NINDS tPA trial, several subjects either did not have available CT scans or 




second component could not be calculated and subsequently the baseline mRS could not 
be estimated. These subjects were not excluded from the analysis unless they died in the 
first week of follow-up, leaving them with only one observed mRS score (5/624). 
Therefore, the total number of subjects included in the MSMM was 619, where 320 were 
randomized to receive tPA and 323 to receive placebo.  
 
Figure 4.1: Baseline mRS score from summed standardized component scores for: (a) NINDS tPA and (b) 
ALIAS. 
4.3.1 The Longitudinal Data 
 In the ALIAS Trial, a small number of subjects withdrew consent or were lost-to 
follow-up prior to the 30 day visit and had only one observation available, the estimated 
baseline mRS (17/1275). Excluding these subjects, a total of 1258 were included in the 




Appendix 4C, baseline characteristics of the 17 excluded subjects are summarized 
alongside those of the subjects that were not excluded. No notable differences exist 
between the groups and thus the exclusion of these subjects should be inconsequential in 
the analysis.   
4.3.2 Development of MSMM for the NINDS tPA Study and ALIAS 
In order to analyze panel data with continuous-time Markov chains it is important to 
consider which transitions can realistically occur in continuous time. When states 
represent severity it is assumed that in order for a subject to transition from one state to 
another non-adjacent state they also transition through the intermediate states. Thus, a 
reduced transition intensity matrix should be estimated, where non-adjacent state 
transitions are fixed to equal zero. The exception is when a state represents death. The 
reality is that a subject can die from any state.  
 In practice, if there is not enough information from the data, on a certain transition 
rate, more transition intensities may need to be set to zero [4]. State tables display counts 
of the pairs of transitions between states in successive observation times and summarize 
them in frequency tables of previous state against current state. These state tables can be 
used to identify counts that are too few to model. 
 The state table of all aggregate transtions from the NINDS tPA data (baseline to 
360 days) is displayed in Table 4.2. Even though it is possible for subjects to die from 
any state, it is highly unlikely to occur from states 1, 2, 3 or 4. This is not surprising as 
subjects are only observed over the course of one year. The relatively healthy subjects 




the table is stratified by time for the piecewise model and again by treatment, the 
frequency of death from the healthier states (1, 2, 3 and 4) is too small to estimate the 
transition intensities. As a result, the original model was modified to no longer allow 
death from any state. Constraints were imposed such that death was only allowable from 
states 5 and 6.  
Table 4.2. NINDS tPA state table. 
 
To (state j) 
 
1 2 3 4 5 6 7 Total 
From (state i) 
        1 206 52 9 3 5 0 2 277 
2 87 245 39 12 23 7 8 421 
3 23 73 85 35 32 14 10 272 
4 13 41 62 148 52 25 10 351 
5 11 26 27 84 187 53 41 429 
6 4 8 7 25 83 142 83 352 
Total 344 445 229 307 382 241 154 2102 
 
 Similarly, when the state table was examined for ALIAS, small counts were 
observed for death from states 1, 2 and 3. The reduced allowable transition matrix for 
ALIAS fixed the intensities from these states to death to equal 0, only allowing the 
intensities from 4, 5 and 6 to death to be estimated. 
4.3.3 Analysis of the NINDS tPA Study and ALIAS 
The entries of the transition intensity matrices were estimated by applying the maximum-
likelihood method and accounting for the two constant intervals partitioned at time 
.333t   (representative of 7-10 days on a month-long interval) in the NINDS tPA trial 
and time 1t   (representative of 30 days) in ALIAS. Analysis was performed using the 




 For the NINDS tPA trial, using a likelihood ratio test to compare the piecewise 
model including treatment (-2LL = 6251) to one without treatment (-2LL = 6282), the 
model with treatment was preferred, indicating a statistically significant treatment effect 
on the transition rates (p = 0.002, df = 12). It is interesting to note that in models 
excluding estimated baseline mRS, the comparison of a model with treatment (-2LL = 
4033) adjusting for baseline NIHSS to one without treatment (-2LL = 4053) failed to 
detect a statistically significant treatment effect (p = 0.053, df = 12). 
 In ALIAS, using a likelihood ratio test to compare the piecewise model including 
treatment (-2LL = 12730) to one without (-2LL = 12745), the reduced model was 
preferred, indicating no significant treatment effect on the transition rates (p = 0.29, df = 
13), confirming the results from the primary analysis of the trial [43]. 
 For NINDS tPA, after comparing the empirical distribution to the observed test 
statistic of 31.18, the p-value from the bootstrap procedure was 0.04 which is larger than 
the observed p-value of 0.002 but still indicative of a significant treatment effect. For 
ALIAS, the p-value calculated from the bootstrap procedure, where the test statistic from 
the analysis of the original sample was 15.25, was 0.49 which is also larger than the 
observed p-value of 0.29 but results in the same conclusion that there is no a significant 
treatment effect.  
 Table 4.3 shows the transition intensities estimated in the piecewise-constant 
model for the NINDS tPA Stroke Study. Transition rates differ between the placebo and 




(Table 4.4). A hazard ratio greater than one indicates that the rate of transition is higher in 
the treatment group. 
 The only statistically significant hazard ratio was from state 2 to state 3 (HR = 
0.51). This can be interpreted as the most significant impact of tPA is to reduce the 
hazard of transitioning from mRS = 1 to mRS = 2. The other hazard ratios, although not 
statistically significant, suggest a trend of tPA reducing the hazard of negative transitions. 
Table 4.3. Maximum-likelihood estimates of transition rates among states. 
 Placebo tPA 
Transition 0 ≤ t ≤ 0.333 t > 0.333 0 ≤ t ≤ 0.333 t > 0.333 
12 10.83 (2.36, 49.71) 0.09 (0.06, 0.14) 7.91 (1.89, 33.06) 0.07 (0.05, 0.09) 
23 19.30 (6.07, 61.37) 0.09 (0.06, 0.15) 9.75 (3.15, 30.22) 0.05 (0.03, 0.07) 
34 12.84 (6.53, 25.28) 0.19 (0.12, 0.32) 16.59 (7.09, 38.86) 0.25 (0.14, 0.44) 
45 24.03 (10.50, 54.98) 0.12 (0.08, 0.19) 16.07 (6.71, 38.50) 0.08 (0.05, 0.13) 
56 2.97 (1.92, 4.59) 0.05 (0.04, 0.10) 2.63 (1.70, 4.07) 0.05 (0.03, 0.09) 
57 0.48 (0.27, 0.86) 0.05 (0.04, 0.07) 0.46 (0.26, 0.83) 0.05 (0.03, 0.07) 
67 0.50 (0.28, 0.88) 0.12 (0.09, 0.18) 0.60 (0.35, 1.02) 0.15 (0.10, 0.21) 
21 7.53 (1.64, 34.55) 0.08 (0.05, 0.11) 7.54 (1.85, 30.72) 0.08 (0.06, 0.10) 
32 18.06 (5.49, 59.44) 0.23 (0.16, 0.32) 20.59 (6.43, 65.91) 0.26 (0.18, 0.36) 
43 14.15 (6.74, 29.71) 0.22 (0.15, 0.32) 14.06 (6.09, 32.46) 0.22 (0.15, 0.33) 
54 6.29 (2.59, 15.26) 0.20 (0.15, 0.27) 6.86 (2.86, 16.46) 0.22 (0.16, 0.30) 
65 3.08 (2.01, 4.72) 0.23 (0.17, 0.32) 2.46 (1.61, 3.77) 0.18 (0.13, 0.26) 
 
Table 4.4. Hazard ratios (95% CI). 
12 0.73 (0.43, 1.23) 
23 0.51 (0.28, 0.90) 
34 1.29 (0.66, 2.52) 
45 0.67 (0.38, 1.17) 
56 0.88 (0.53, 1.48) 
57 0.96 (0.55, 1.66) 
67 1.20 (0.75, 1.92) 
21 1.00 (0.62, 1.62) 
32 1.14 (0.71, 1.83) 
43 0.99 (0.59, 1.68) 
54 1.09 (0.72, 1.65) 





4.4 Summary and Discussion 
Dichotomization of ordinal outcomes is common but results in a loss of information and 
can reduce statistical power. Some patients with severe disability at baseline may never 
have the potential to achieve success as defined by the dichotomy. Thus, the prognostic 
heterogeneity of subjects does not allow for potential equal contribution to the estimation 
of treatment effect for all subjects with a dichotomized outcome [9]. 
 A number of alternative methods for ordinal outcome data have received attention 
in recent years [93]. Linear regression and analysis of variance have been suggested 
where the ordinal outcome is treated as a continuous variable. Summary statistics from 
these models do not have straightforward interpretations because non-integer values from 
ordinal scales do not have a clear meaning. 
 A number of ordinal analyses have also been suggested. Ordinal logistic 
regression, under the assumption of proportional odds, assumes an identical effect of the 
predictors for each cumulative probability [45]. If the proportional odds assumption 
holds, statistical power can be increased as compared to analysis using a strict dichotomy. 
The score test for assessing the proportional odds assumption, however, is 
anticonservative. If the assumption fails, this analysis could mask important effects at one 
end of the ordinal outcome [46]. The partial proportional odds model relaxes this 
assumption and includes a term that allows the odds ratios to increase proportional to the 
outcome scale [46]. Alternatively, the cumulative logit model allows for the calculation 
of odds ratios for each adjacent category of response in relation to covariates and does 




proportional odds and cumulative logit models is that they can require a larger sample 
size to be adequately powered. 
 The sliding dichotomy is another alternative method for the analysis of ordinal 
outcomes. It allows for the definition of success to vary based on patient-specific baseline 
prognostic variables while maintaining a dichotomized outcome, however, there are no 
guidelines for selection of number of prognostic groups nor cut points for those groups 
[48]. Poor selection of these groups could lead to a reduction in power. Furthermore, 
while the sliding dichotomy allows for baseline severity adjusted outcome, it still ignores 
any non-successful transitions [94].  
 The Cochran-Mantel Haenszel (CMH) shift test can also be used to analyze the 
distribution of ordinal data [7]. This test can show whether a treatment causes a 
significant shift toward good outcome. Shift analysis can account for ordered categories, 
has no distributional assumptions and is easy to implement. However, it is not feasible for 
large scale clinical trials with non-simple randomization schemes because it can only 
accommodate a limited number of covariates. There are also no summary statistics that 
appeal to a clinical audience so proportional odds logistic regression is often used in 
conjunction with the CMH test to provide an estimate of treatment effect [44]. In 
addition, shift analysis assumes that a treatment effect exists only in one direction, where 
only benefit is considered, not harm.  
 An approach to transform the mRS into a patient-centered outcome measure was 
recently proposed [53]. The chosen patient-centered outcome measure was utility, which 




derived for each level of the mRS by averaging utility values derived in two studies, 
using two different methods. Analysis using the utility weights is straightforward as the 
weights have already been defined and the utility-weighted mRS is analyzed using a t 
test. Though this method is easy to implement and provides greater statistical power, it is 
based on only two populations and may not be representative of patients in other 
locations. In addition, the utility values do not have as clear of an interpretation as some 
other analysis methods. 
 None of the previously mentioned methods utilize the repeated measures even 
though outcome is collected over time. In fact, a literature search for repeated measures 
analysis of acute stroke trial data only returned one article where a generalized estimating 
equations approach was used for repeated measures analysis [11]. This approach only 
considered the dichotomized outcomes from the NINDS tPA study. The work presented 
here is the first known study of the repeated measures acute stroke therapy data using the 
ordinal scale. 
 The results presented in this manuscript are the first to estimate a missing baseline 
ordinal outcome for use in a MSMM. In the case of ischemic stroke occurrence and 
treatment much of the progression or recovery experienced by a patient is expected to 
occur early. Functional outcome measures are not suitable at baseline and as a result, 
functional changes over time from baseline cannot be measured. Therefore, latent 
estimation the functional baseline was warranted, allowing for inclusion of an 





 Using the longitudinal data, including the estimated baseline, this work showed 
that there are differences in the rate of transitions between the treatment and placebo 
groups in the NINDS tPA trial, confirming the results of the primary analysis while 
allowing for examination of the effect on all adjacent-state transitions. The ability to 
estimate the intensities for all adjacent-state transitions allowed for examination of the 
most significant effect of treatment. Specifically, it was determined that the most 
significant impact of tPA is reduction the hazard of transitioning from mRS = 1 to mRS = 
2. In addition, the conclusion of no treatment effect in the ALIAS Trial data was also 
consistent with the primary analysis from that trial.  
 In the MSMM of the NINDS tPA data, where the estimated baseline was not 
included and the model adjusted for baseline NIHSS instead, as is done in most other 
types of analysis of the mRS, the effect of treatment was only marginally significant. 
Thus, it seems as though inclusion of the estimated baseline mRS improved the ability to 
detect a treatment effect. It is hypothesized that the inclusion of the latently estimated 
baseline mRS is improves the model because of the acute nature of ischemic stroke 
therapy and the expected early recovery and disease progression directly following 
treatment. 
 The MSMM can incorporate longitudinal ordinal data and provide clinically 
interpretable summary statistics to describe covariate effects on all transition rates and 
sojourn times. Estimation of transition rates can describe treatment effect in a much finer 
gradient than modeling collapsed ordinal scale allowing for a more comprehensive 




specific hypotheses to be tested-- for example a likelihood ratio test could be used to test 
whether the effect of treatment is the same for all forward transitions and backward 
transitions [59]. 
 Another benefit of these models is the potentially decreased sample size needed to 
detect a treatment effect. A previous simulation study indicated that the power of 
MSMMs applied to acute onset clinical trial data was significantly increased when the 
number of follow-up visits was increased [93]. Future trials could collect the ordinal 
outcome more frequently over the course of follow-up, increasing the power to detect 
differences using this modeling technique. 
 A limitation of MSMMs is that they are computationally intensive, especially 
when using bootstrapping to obtain the bootstrap empirical distribution. In addition, use 
of these models requires a priori decisions about the transitions that can realistically 
occur, which may be a data driven decision. Interpretation of the full model could 
potentially be overwhelming, as there are many parameters that describe the effect of one 
covariate; however, the model also allows for testing whether the effect of a covariate is 
the same for certain transitions, which could reduce the number of parameters. The 
flexibility to estimate the full or reduced model allows a number of clinical questions to 
be answered using one approach. 
 Future directions could include more complex methods for baseline estimation. 
For example, a Bayesian PCA could be used in alternative baseline estimation procedure. 
This method could potentially address the uncertainty of the assigned baseline scores via 




methods presented for estimation could be extended to cases where more than two 
components were used in the estimation procedure. 
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Appendix 4A: modified NIHSS summary 
In this appendix, Table 4.1A is presented, which shows the 15 items of the NIHSS. The 





Table 4.1A. The Modified National Institutes of Health Stroke Scale 
Summary. 
1A Level of Consciousness 
 
0 = Alert 
1 = Not alert, obtunded 
3 = Unresponsive 
1B 
 
LOC Questions 0 = Answers both correctly 
1 = Answers one correctly 
2 = Answers neither correctly 
1C 
 
LOC Commands 0 = Performs both tasks correctly 
1 = Performs one task correctly 
2 = Performs neither task 
2 
 
Best Gaze 0 = Normal 
1 = Partial gaze palsy 
2 = Total gaze palsy 
3 
 
Visual 0 = No visual loss 
1 = Partial hemianopia 
2 = Complete hemianopia 
3 = Bilateral hemianopia  
4 Facial Palsy 
 
0 = Normal 
1 = Minor paralysis 
2 = Partial paralysis  
3 = Complete paralysis 




0 = No drift 
1 = Drift before 10 seconds 
2 = Falls before 10 seconds 
3 = No effort against gravity 
4 = No movement 




0 = No drift 
1 = Drift before 10 seconds 
2 = Falls before 10 seconds 
3 = No effort against gravity 
4 = No movement 
7 
 
Limb Ataxia 0 = Absent 
1 = Present in one limb 
2 = Present in two limbs 
8 
 
Sensory 0 = Normal 
1 = Mild to moderate sensory loss 
2 = Severe to total sensory loss 
9 Best Language 
 
0 = No aphasia, normal 
1 = Mild to moderate aphasia 
2 = Severe aphasia 
3 = Mute or global aphasia 
10 
 
Dysarthria 0 = Normal 
1 = Mild to moderate 
2 = Severe 
11 Extinction and Inattention (Neglect) 
 
0 = No abnormality 
1 = Mild 




Appendix 4B: data reduction using principal component analysis 
When applied to a set of variables, PCA can group correlated variables into a smaller set 
of composite variables (principal components). The resulting linear combinations of 
variables account for as much variability in the data as possible and can be used to 
calculate component scores. A number of methods exist for computation of component 
scores. Non-refined methods are simple, easy to compute and easy to interpret, while 
refined methods are more complex and exact [96]. Refined computation methods are 
generally less stable across samples; hence, a non-refined method is implemented for the 
motivating data sets. Of the non-refined methods, the summation of standardized 
variables is preferred when the standard deviations of the raw data vary widely, as was 
found in the NINDS tPA and ALIAS data. 
 PCA was used to group measures of severity (individual items of the NIHSS) and 
other baseline variables known to be associated with functional ability (age, baseline 
glucose, time from stroke onset to randomization and ASPECTS score) into components 
and calculate component scores. For the analysis using PCA, variables were reformatted 
so that the direction of effect was consistent across all candidate variable and 
standardized scales were used. Component scores from PCA are more intuitive if the 
expected relationship with the variables and outcome is in the same direction. For 
example, increased age increases the risk of a negative outcome. All of the variables 
included in the PCA are positively correlated with bad outcome except ASPECTS. A 
smaller ASPECTS is predictive of negative outcome. For interpretation, the direction of 





Figure 4.1B. Scree plot of eigenvalues from PCA of baseline variables from: (a) NINDS tPA and (b) 
ALIAS. 
 
 In the process of determining the number of components to retain from the PCA 
analysis, the eigenvalues of the correlation matrix were visually assessed using scree 
plots (Figure 4.1B). From this illustration it can be seen that the line flattens after the 
second component in the scree plot for both NINDS tPA (a) and ALIAS (b) and thus the 






































assess how strongly the components and variables are related, the component loadings for 
retained components were examined. Component loadings can be interpreted as the 
correlation between an observed variable and a component. A general rule of thumb 
deems components with loadings of at least |.4| highly explanatory [97]. 
  The loadings for the first two components are displayed in Table 4.1B. Based on 
the criteria outlined above, baseline glucose, time from onset to randomization, and 
individual NIHSS items Q1A and Q07 were not included in the component score 
calculation for NINDS tPA. Age, baseline glucose, time from onset to randomization, and 
individual NIHSS items Q07 and Q10 were not included in the component score 
calculation for ALIAS. 
Table 4.1B. Factor loadings on components based on PCA. 




 1 2 1 2 
Age 0.15 -0.03 0.16 0.13 
Baseline glucose 0.10 -0.04 0.06 -0.02 
Stroke onset to randomization -0.08 -0.06 0.03 -0.04 
NIHSS item     
Q1A – Level of Consciousness (LOC) 0.38 0.39 0.32 0.42 
Q1B – LOC Questions 0.78 -0.18 0.80 -0.01 
Q1C – LOC Commands 0.75 -0.01 0.78 0.14 
Q02 – Best Gaze 0.37 0.66 0.20 0.71 
Q03 – Visual  0.36 0.61 0.25 0.64 
Q04 – Facial Palsy 0.22 0.50 0.01 0.48 
Q5A – Motor Arm Left -0.39 0.77 -0.63 0.58 
Q5B – Motor Arm Right 0.84 -0.20 0.82 -0.01 
Q6A – Motor Leg Left -0.25 0.74 -0.53 0.56 
Q6B – Motor Leg Right 0.80 -0.11 0.76 0.03 
Q07 – Limb Ataxia -0.20 -0.21 -0.15 -0.24 
Q08 – Sensory 0.20 0.60 -0.02 0.54 
Q09 – Best Language 0.86 -0.19 0.87 -0.03 
Q10 – Dysarthria 0.60 0.04 0.35 0.22 
Q11 – Extinction and Inattention 0.15 0.70 -0.09 0.68 




 Each of the variables deemed important with the cutoff of >|.4| on the first two 
components were standardized to range [0, 1]. The standardized values of variables that 
loaded high on each component were summed to calculate the component scores as 
follows: 
 NINDS tPA Component Score 1 =  
 Q1B + Q1C + Q5B + Q6B + Q09 + Q10  
 NINDS tPA Component Score 2 =  
 Q02 + Q03 + Q04 + Q5A + Q6A + Q08 + Q11 + ASPECTS 
 ALIAS Component Score 1 =  
 Q1B + Q1C + Q5B + Q6B + Q09  
 ALIAS Component Score 2 =  
 Q1A + Q02 + Q03 + Q04 + Q5A + Q6A + Q08 + Q11 + ASPECTS.  









Appendix 4C: baseline characteristics of ALIAS subjects included and excluded 
from MSMM analysis 
In this appendix, Table 4.1C is presented with baseline characteristics of the 17 ALIAS 
subjects excluded from the analysis because of withdrawn consent or lost-to-follow-up 
prior to the 30 day visit in combination with all mRS scores missing post-baseline. 
Table 4.1C. Baseline Characteristics of the Subjects. 
Characteristic Included 
(N = 1258) 
Excluded 
(N = 17) 
Age [mean (SD)] 66.1 (13.6) 62.6 (15.3) 





[n (%)]  
White 969 (77.0) 13 (76.5) 
Black 197 (15.7) 3 (17.7) 
Asian 60 (4.8) 0 (0.0) 
American Indian/Alaska Native/First 
Nations People 
7 (0.6) 0 (0.0) 
Native Hawaiian or Pacific islander 3 (0.2) 0 (0.0) 





Non-Hispanic/Latino 1147 (91.2) 15 (88.2) 
Hispanic/Latino 60 (4.8) 2 (11.8) 







Hypertension 911 (72.4) 10 (58.8) 
Atrial fibrillation 257 (20.4) 2 (11.8) 
Past congestive heart failure 55 (4.4) 1 (5.9) 
Past myocardial infarction 155 (12.3) 5 (29.4) 
Past stroke 238 (18.9) 6 (35.3) 
Past transient ischaemic attack 157 (12.5) 2 (11.8) 
Diabetes mellitus 261 (20.8) 4 (23.5) 
Hyperlipidemia 554 (44.0) 8 (47.1) 
Peripheral vascular disease 75 (6.0) 1 (5.9) 
 









Systolic blood pressure, mm Hg  156.9 (29.0) 157.3 (31.3) 
Plasma glucose, mmol/L 7.4 (3.2) 7.9 (3.3) 
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Abstract 
Background and Purpose – Historically, ordinal measures of functional outcome have 
been dichotomized for the primary analysis in trials of acute stroke therapy. A number of 
alternative methods to analyze the ordinal scales have been proposed, with an emphasis 
on maintaining the ordinal structure as much as possible. In addition, despite the 
availability of longitudinal outcome data in many trials, the primary analysis consists of a 
single endpoint. Inclusion of information about the course of disease progression allows 
for a more complete understanding of the treatment effect.  
Methods – Multistate Markov modeling, which allows for the full ordinal scale to be 




the ordinal modified Rankin Scale (dichotomous-logistic regression; continuous-linear 
regression; ordinal- shift analysis, proportional odds model, partial proportional odds 
model, adjacent categories logit model; sliding dichotomy; utility weights; repeated 
measures). Each of the methods is used to re-analyze the National Institute of 
Neurological Diseases and Stroke tissue plasminogen activator study.  
Results – All methods detected a statistically significant treatment effect except the 
multistate Markov model without predicted baseline (p=0.053). The multistate Markov 
model allows for a more refined examination of treatment effect and describes the 
movement between modified Rankin Scale states over time which may provide more 
clinical insight into the treatment effect. 
Conclusions – Multistate Markov models are feasible and desirable in describing 
treatment effect in acute stroke therapy trials. Future trials could increase power to detect 
a treatment effect using these models by collecting the outcome more frequently. 
Keywords 






A number of potential explanations for the failure of most acute stroke therapy trials to 
show efficacy have been discussed, including differences in preclinical and clinical 
models, inappropriate inclusion criteria, and poor methodological and statistical standards 
[6]. Specifically, there has been a recent emphasis on exploring alternative outcomes and 
analytic methods for stroke therapy trials.  
The modified Rankin Scale (mRS) is the most commonly chosen primary 
outcome measure in clinical trials of acute stroke therapy [2]. Despite the ordinality of 
the outcome measure, many trials have dichotomized the mRS for the primary analysis 
[7]. In general, ignoring these differences and dichotomizing does not allow for 
examination of the treatment effect at finer gradients of the scale and can result in a loss 
of statistical power [1]. Any reduction in power may result in failure to find a clinically 
meaningful treatment effect during analysis of the data. The mRS should be analyzed in 
such a way that maintains the original structure of the scale as much as possible, using 
continuous or ordinal approaches [1, 3]. 
 A number of alternative methods have been proposed to improve the analysis of 
the mRS. Some trials have analyzed the mRS as a continuous outcome, utilizing t-tests or 
linear regression [71]. Other trials have used the Cochran-Mantel Haenszel (CMH) shift 
test to analyze the distribution of the mRS, where the primary outcome is a favorable 
shift toward better functional outcome [7]. Ordinal logistic regression has also been 
proposed and applied in re-analysis of stroke trial data [46]. The proportional odds model 




powered. In cases where the assumption was not justifiable, the partial proportion odds 
model (PPOM) or the adjacent categories logit (ACAT) has been used [46]. A popular 
alternative to continuous, ordinal and strict dichotomous analysis is responder analysis or 
the sliding dichotomy, where the definition of success is allowed to vary depending on 
baseline severity [48]. Most recently, a utility weighted mRS (UW-mRS) was derived to 
provide a patient centered metric of the degree of benefit or harm of a treatment that can 
be analyzed with a t-test or linear regression [53, 98]. 
 A drawback of the outcome measures and analytic strategies listed above is that 
each analyzes data from a single endpoint, commonly the 90 day outcome, for the 
primary analysis despite the availability of repeated response measures collected over the 
course of longitudinal follow-up. Inclusion of information about the course of disease 
progression, using the longitudinal data, allows for a more comprehensive understanding 
of the benefit of a treatment [99]. None of the previously mentioned methods have 
utilized the repeated measures data. A literature search for repeated measures analysis of 
acute stroke trial data returned only two articles where a generalized estimating equations 
approach was used for repeated measures analysis of the mRS [11, 58]. 
 Most recently, the Multistate Markov model (MSMM) was proposed for analysis 
of the mRS [93, 100]. The MSMM analyzes repeated measures data with ordinal 
outcomes. These types of models describe how a subject moves between a series of 
disease states over time, which is desirable in the description of disease processes that 
naturally move through increasing stages of severity [59]. Results suggest that the 




mRS data in some scenarios [93]. MSMMs can provide a better clinical understanding of 
the disease process since the information from the entire course of the disease is used to 
estimate the parameters of the model. 
 The purpose of this article is to demonstrate the MSMM as an approach for 
analysis of the mRS. The MSMM and the alternative methods listed above will be used to 
re-analyze the National Institute of Neurological Disorders and Stroke (NINDS) tissue 
plasminogen activator (t-PA) trial data. The results from each of the analytical analysis 
approaches will be compared with the results using the MSMM approach. 
5.2 Materials and Methods 
5.2.1 Trial Data 
The seminal NINDS t-PA trial showed a consistently significant effect of t-PA using a 
global test of four outcomes (Barthel Index, mRS, Glasgow Outcome Scale and NIHSS) 
in the analysis of the primary outcome at 90 days post-stroke [39]. In addition to the 90 
day primary outcome assessment, the mRS was also collected at 7-10 days, 180 days and 
360 days from randomization.  
 Acute stroke requires immediate attention and treatment, posing a challenge to 
assess baseline outcome measures for clinical trials. Thus, the mRS is not obtainable at 
baseline and most often analysis is adjusted for baseline severity using the NIHSS [80]. 
Much of the progression or recovery experienced by a patient suffering from an acute 
onset disease is expected to occur early on. Moreover, typically, the goal of a treatment or 
therapeutic action is improvement in patient health compared to their baseline measure. 




 A prediction procedure using principal component analysis (PCA) for data 
reduction of baseline variables known to be correlated with functional ability was 
previously described [100]. Briefly, PCA is a statistical data reduction method that, when 
applied to a large set of variables, can group correlated variables into a smaller set of 
important composite variables, or components. The PCA grouped measures of severity 
(individual items of the NIHSS) and other baseline variables known to be associated with 
functional ability (age, baseline glucose, time from stroke onset to randomization and the 
Alberta Stroke Program Early CT score) into components to calculate component scores. 
The resulting component scores were used to assign the latent baseline mRS score and 
thus creating a comparable baseline mRS for analysis purposes. 
5.2.2 Multistate Markov Models 
In this paper, continuous-time MSMMs are used to describe the progression and recovery 
between mRS levels, or the disease states, over time. The main assumption of the 
MSMM is that the probabilities governing the transition between states only depend on 
the current state occupied by an individual, and not on previous disease history.  
 Death (mRS = 6) is known as an absorbing state because transitions out of this 
state cannot occur and mRS scores of 0 to 5 are examples of transient states, where 
transitions are allowed between the states. The data from the NINDS t-PA trial were 
observed at arbitrary times that were specified in advance so exact times of state 
transitions are unknown. Data of this type, observations of a continuous process at 
discrete times, are called panel data. Because the underlying disease process is 




order for a subject to transition from one state to a non-adjacent state they also transition 
through the intermediate states [4]. Thus, the general MSMM for panel data only 
estimates adjacent state transitions and transitions to death from any state. The allowable 
transitions between transient and absorbing states for the general model of the mRS are 
illustrated in Figure 5.1, where arrows indicate the allowed transitions between states. 
 MSMMs of panel data are governed by transition intensities that depend on time 
and individual level or time-dependent covariates. The transition intensities represent the 
instantaneous risk of transition between two mRS scores. Commonly, the transition 
intensities are assumed to be constant over time but this is often an unrealistic 
assumption. If the assumption fails, a model with piecewise-constant transition intensities 
can be used. This allows for the transition intensity matrices to change at breakpoints, 
remaining constant between the breakpoints. In addition to transition intensities, 
transition probabilities can also be estimated based on the observed transition rates using 
maximum likelihood estimation [4]. When modeling covariates in a MSMM, hazard 









 Likelihood ratio test (LRT) statistics are used to compare nested MSMMs. A 
reduced model is nested in a more complex model if all of the terms in the smaller model 
occur in the larger model. If two nested models are compared and the test is significant, 
then the more complex model fits the data better than the reduced model. LRTs are used 
to determine the significance of covariates and to compare models with constant 
transition intensities to ones with piecewise-constant intensities. 
5.2.3 Statistical Analysis and Assumptions 
For analyses using a fixed dichotomy, favorable outcome was defined as mRS ≤ 1, as 
was done in the primary paper [38]. The PPOM includes an additional term using a 
second parameter that allows for the ORs to increase proportional to the outcome scale. 
This PPOM, the restricted PPOM, is used when there is a linear deviation from the 
proportional odds assumption required for the POM, which is true of the NINDS t-PA 
data [46]. For the sliding dichotomy analysis, favorable outcome was defined to be 
consistent with previous re-analysis of the NINDS t-PA data where mRS = 0 for subjects 
with mild stroke (NIHSS < 7), mRS ≤ 1 for subjects with moderate stroke (NIHSS = 8-
14) and mRS ≤ 2 (NIHSS > 14) [101]. The UW-mRS values were derived by averaging 
patient centered and person-tradeoff studies and are reported by Chaisinanunkul et al 
[53]. 
 The ACAT and MSMMs were fit in R statistical software version 3.3.0 using the 
VGAM and msm packages, respectively. All other analysis was completed in SAS 9.4. 
When appropriate, analyses were adjusted for baseline NIHSS, which is known to be 




MSMM with predicted baseline mRS did not include baseline NIHSS because baseline 
severity is already accounted for. The shift analysis was also not adjusted for baseline 
severity as the test does not accommodate continuous covariates. Shift analysis for the 
NINDS t-PA data was previously repeated for different stratifications of the NIHSS and 
the results are reported elsewhere [7]. 
5.3 Results 
The analysis presented in this section is based on 619 subjects that had mRS scores 
recorded at 90 days. The raw 90 day mRS outcome distributions for the placebo and t-PA 
groups are presented in Table 5.1. There are slight differences in the results presented in 
this section compared with other re-analyses of the trial because the raw observed values 
are used rather than the intent to treat imputation.  
Table 5.1. NINDS t-PA 90 day mRS Counts (%). 
 
































54 (8.7) 309 
Total 90 124 60 85 103 40 117 
 
 
 Figures 5.2 and 5.3 display mRS scores over time for the control and t-PA groups, 
respectively. These plots, called Sankey plots, show the percentage of subjects with each 
mRS score at each follow-up visit as well as the change in the number of subjects with 
each score over time [74]. The longitudinal bar chart shows the percentage of subjects 





Figure 5.2. Sankey plot of NINDS t-PA control group subjects mRS scores over time. 
 
 




the change in the number of subjects in each state, over time. A thicker link is indicative 
of more subjects transitioning between the two states. In the 90 day mRS alone, there are 
differences between the groups across the entire ordinal scale that are ignored in a 
traditional dichotomized analysis. The use of one follow-up visit also results in a loss of 
information as there are differences in the distribution of the mRS as well as the 
transition rates over the entire follow-up period. Additionally, the inclusion of the 
predicted baseline mRS allows one to observe the differences in the transition rates 
between treatment groups in the crucial window immediately following randomization 
and during the acute treatment phase. All of these differences can be measured and 
described using MSMMs and are not accounted for using other ordinal data analysis 
methods. 
 In the general MSMM (Figure 5.1), some of the parameters estimated were close 
to zero. Specifically, the transition intensities to death from mRS = {0,1,2,3}  were all 
very small. When there is not enough information from the data on certain transition 
rates, more intensities may need to be set to zero [4]. Thus, the general model was 
reduced, no longer allowing death from any state. Constraints were imposed such that 
death is only allowable from mRS = 4 or mRS = 5. 
 The results from all methods are presented in Table 5.2. The results are consistent 
with previously reported re-analyses of the NINDS t-PA data with minor, insignificant 
differences in estimates due to the adjustment for the NIHSS and the use of the raw mRS 
data versus intent to treat [11, 46, 53, 94, 102]. Table 5.3 presents a review of the 




Table 5.2. Results from previously used methods for analysis of the mRS. 
Method Outcome Measure Summary Statistic  (95% CI) p 
Logistic regression mRS at 90 d (0-1 vs. 2-
6) 
OR = 2.04 (1.39, 2.99) 0.0003 
Linear regression mRS at 90 d 
(continuous) 
Diff. in means = 
0.50 
- 0.0073 
Shift analysis mRS at 90 d - - 0.0017 
POM mRS at 90 d OR = 1.41 (1.01, 1.81) 0.0172 
PPOM  
(linear trend) 
mRS at 90 d 
1-6 vs. 0 
2-6 vs. 0-1 
3-6 vs. 0-2 
4-6 vs. 0-3 
5-6 vs. 0-4 
















ACAT mRS at 90 d 
1 vs. 0 
2 vs. 1 
3 vs. 2 
4 vs. 3 
5 vs. 4 



















mRS at 90 d (0 if NIHSS 
is 1-7, 0-1 if 8-14 and 0-
2 if >14) 
OR = 1.61 (1.13, 2.28) 0.0080 
Linear regression 
of UW-mRS 





mRS at 7-10, 90, 180 
and 360 d (0-1 vs. 2-6) 




Predicted mRS at 
baseline and mRS at 7-
10, 90, 180 and 360 d 
(0-1 vs. 2-6) 
OR = 1.78 (1.33, 2.38) 0.0001 
MSMM 
(without baseline) 
mRS at 7-10, 90, 180 















































Predicted mRS at 
baseline and mRS 7-10, 













































The results of the MSMM are presented as hazard ratios that estimate the effect of the 
covariate on transition intensities. A hazard ratio above one signifies a positive 
association between treatment and the rate of transition, whereas a hazard ratio of one 
implies no effect. 
 In the MSMM with baseline mRS, treatment with t-PA significantly reduced the 
transition intensity between mRS = 1 and mRS = 2 with a hazard ratio of 0.51 (95% CI: 
0.28, 0.90). None of the other hazard ratios were significantly different from one. This 
finding is consistent with the results of the ACAT model where the only significant OR is 
the one comparing mRS category 2 to mRS category 1. The conclusion drawn from the 
ACAT is that the most relevant impact of t-PA is to reduce the odds of observing a 
category 2 versus a category 1 at 90 days [46]. The results from the MSMM allow for a 
more refined conclusion- the most relevant impact of t-PA is to reduce the hazard of 
transitioning from mRS category 1 to mRS category 2. Therefore, the t-PA is more 
protective of worsening from category 1 rather than promoting improvement from 




Table 5.3. Summary of statistics obtained from each type of analysis of the mRS. 
Method Statistic(s) Interpretation  
Logistic regression OR The odds of good outcome in the 
treatment group versus placebo 
Linear regression Difference of means Improvement of the average mRS score 
in patients that received treatment 
Shift analysis Probability value  
(no effect size or OR) 
The treatment group shifted in a 
favorable direction toward a better mRS 
score versus placebo 
POM Summary odds ratio The odds of a lower mRS the treatment 
group versus placebo 
PPOM ORs for six possible 
dichotomizations of 
mRS 
Treatment has a significant benefit for 
certain definitions of good outcome 
ACAT  ORs the six adjacent 
categories of response 
The treatment group is more likely to 
have smaller mRS for certain adjacent 




OR  The odds of good outcome (defined by 
baseline severity) in the treatment group 
versus placebo 
Linear regression of 
UW-mRS 
Difference of mean 
utility scores 
Improvement of the average utility 




OR The odds of good outcome over the 12-
month period in the treatment group 
versus placebo 
MSMM Hazard ratios for each 
allowable transition 
The hazard (instantaneous risk) of 
transitioning from one mRS state to 




It is not realistic to choose one analytic method that is most appropriate for the mRS for 
all studies because the efficiency varies depending on the expected distribution of the 
treatment effect [3]. In general, ordinal approaches are more efficient when treatment 
effects are distributed over the entire outcome range or when the distribution of treatment 




result of intervention is in the design and sample size calculation stage of a trial. In 
comparison, dichotomous approaches are more efficient than ordinal approaches when 
treatment effects cluster at single-state transitions and can be specified in advance [102]. 
However, it is uncommon for clustering to be predictable. If the clustering cannot be 
predicted, an ordinal approach should be used. 
 In this paper, the dichotomized methods were found to be most statistically 
efficient with respect to power for the NINDS t-PA trial, and inclusion of predicted 
baseline mRS improved the ability to detect a treatment effect in the repeated measures 
analysis. The treatment effect clustered at the transition from mRS category 1 to mRS 
category 2. If limited information were available in the planning stages for this trial to 
confidently predict that the treatment effect would be clustered at that transition, it would 
have been worthwhile to consider an ordinal approach. Acute stroke trials are challenging 
to conduct as there are few centers that can recruit many patients in the early time 
window required for treatment [2]. Because of the low recruitment rate and cost 
associated with conducting acute stroke trials, inefficient statistical tests must be avoided 
to protect from being underpowered.  
 Of the approaches that do not rely on the strict dichotomy, the PPOM and MSMM 
with predicted baseline were the most efficient. The PPOM and MSMM were found to be 
more efficient than linear regression, responder analysis, shift analysis and the UW-mRS 
for analysis of the NINDS t-PA data. The PPOM is represented by ORs for the six 




from one indicating that treatment has a significant benefit whether 0, 0-1 or 0-2 is 
defined as good outcome.  
 Construction of MSMMs provides a more comprehensive view of the disease 
process and allow for exploration of how covariates affect the movement of the process. 
The obvious benefit to using the MSMM is the ability to handle progression and recovery 
simultaneously by estimating transition rates for both. Because of this, the MSMM allows 
for identification of where the treatment effect has the greater impact. Here the effect of 
treatment was greatest in reducing the hazard of transitioning from mRS category 1 to 
mRS category 2. A more clear understanding of the effect of treatment could also be 
beneficial in identifying characteristics of subjects that are more likely to benefit or 
experience harm from a therapy.  
 Another benefit of MSMMs is the potential for decreased sample size. The power 
of MSMMs applied to acute onset clinical trial data was shown to increase significantly 
when the number of follow-up visits was increased [93]. Future trials could collect the 
mRS more frequently, increasing the power to detect differences using this modeling 
technique. This would be a more cost-effective than recruiting more subjects to increase 
power as the telephone assessment of stroke disability with the mRS is reliable in 
comparison with a face-to-face assessment [103]. 
 The MSMM results in a more comprehensive understanding of treatment effect; 
however it also increases the difficultly to determine the sample size to adequately power 
a study using this analysis. Without a summary statistic of effect size, the implementation 




foresight on the expected distribution of the effect of a therapy or treatment. However, 
once the distribution of expected treatment effect has been specified simulation-based 
power analysis for these models is straightforward. Another limitation of MSMMs is the 
increasingly computationally intensive nature as covariates and time-varying intensities 
are added to the models. 
 Future directions of this research may include development of a software package 
to automate the baseline mRS prediction. The package could include more complex 
methods for estimation, potentially Bayesian PCA. Another feature of the package could 
be assistance with data manipulation required to use the msm package in R to fit the 
MSMMs (eg. wide to long format and incorporating exact time of death). In addition, a 
package could be developed to streamline the simulation-based power analyses.  
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6 Overall Discussion 
6.1 Specific Aims Revisited 
The aims of this dissertation are: 
1. To explore the operating characteristics (type I error and power) of MSMMs 
compared with repeated logistic regression used to analyze sparsely populated 
repeated measures ordinal data.  
2. To develop a MSMM approach with piecewise-constant transition intensities that 
incorporates a latent baseline state. 
3. Analyze acute stroke therapy trial data using the methods developed in Aim 2 and 
compare the results with those from alternative methods previously suggested for 
the analysis of the mRS. 
6.2 Summary and Conclusions 
This work focuses on the use of MSMMs to analyze sparsely populated and 
longitudinally collected ordinal data. The mRS score from acute stroke therapy trials was 
the motivating example. To determine whether MSMMs were feasible as an analytic 
method for sparsely populated ordinal data, the operating characteristics are investigated 
using simulation studies in Aim 1. Results indicate that MSMMs can be a more efficient 
approach than repeated measures logistic regression to analyze sparsely populated ordinal 
data. There are also situations where dichotomization might not lose efficiency and may 
be more powerful than the MSMM. Depending on the observed data structure and 




that increasing the number of follow-up visits can dramatically improve power to detect a 
treatment difference. Thus, we recommend that future acute stroke therapy trials collect 
the mRS more frequently, increasing power to detect treatment group differences. 
Increasing the frequency of outcome collection could be more cost-effective than 
recruiting more subjects since the telephone assessment of the mRS is as reliable as the 
face-to-face assessment [103]. 
 Given that the MSMM is an approach that could realistically analyze sparsely 
populated ordinal data, a latent baseline estimation procedure is developed in Aim 2. 
Methods that analyze only one time point have traditionally adjusted for baseline severity 
using the NIHSS score because the mRS score is not available at baseline. When 
modeling data longitudinally, the transition from baseline to first follow-up is important 
because much of the progression or recovery experienced by a patient suffering from an 
acute onset disease is expected to occur early on. Inclusion of the latent baseline in a 
piecewise-constant MSMM improves efficiency to detect a treatment effect as compared 
to the MSMM without baseline that adjusted for baseline NIHSS. 
 In the application to the NINDS t-PA trial in Aim 3, the MSMM with baseline has 
proven to be an efficient method of analysis, as compared to many of the other popular 
methods for the mRS. While dichotomized analysis is the most powerful for this 
particular data set, for most trials, prediction of the clustering of treatment effect a priori 
is not realistic. If the treatment effect clustering is predicted incorrectly, the dichotomized 
statistical test becomes inefficient. For trials where the treatment effect is expected to be 




predicted, methods that analyze the full ordinal scale should be used [3]. The MSMM 
with estimated baseline is comparable in efficiency to the PPOM and the two methods 
outperform the other ordinal methods. The MSMM allows for direct identification of 
where the treatment effect is most significant and the PPOM does not. 
 The goal of this dissertation is to lay the foundation for the use of MSMMs in 
practice to analyze ordinal data, specifically data from acute stroke therapy trials. We 
conclude, from the example presented, that the MSMM with latent baseline mRS is as 
efficient, if not more, than other methods currently used to analyze acute stroke therapy 
trial data. A limitation of this work is that comparison of efficiency of other methods is 
only done for data from one trial. The “best” method for analysis of the mRS will change 
depending on the distribution of the treatment effect. Thus, future work should consider 
data from other trials to better understand the comparative efficiency of the MSMM.  
 This work supports the use of MSMMs for acute stroke therapy trial but 
immediate implementation of these models for the primary analysis of new studies is 
likely not feasible because of lack of readily available software to design a study that uses 
MSMM analysis. The MSMM is a great tool to identify the finer details of the treatment 
effect but the complexity of the model makes determination of sample size needed to be 
adequately powered to detect a treatment effect difficult. Future work would explore how 
to appropriately power a new study using MSMM. Without a summary statistic of effect 
size, the implementation of these models in the analysis of the primary outcome in trials 




However, once the distribution of expected treatment effect has been specified 
simulation-based power analysis for these models is straightforward.  
 Additional future directions of this research include development of a software 
package to automate the baseline mRS estimation. Another feature of the package could 
be assistance with data manipulation required to use the msm package in R to fit the 
MSMMs. Finally, the package could also contain functions to streamline the simulation-
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